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ABSTRACT 
BACKGROUND: 
 It has been hypothesized that inactivation of p16 plays a vital role in 
evolution of potentially malignant disorders [Epithelial Dysplasia, Oral 
SubmucousFibrosis (OSF)] and in Oral Squamous Cell Carcinoma (OSCC). We 
wanted to ascertain the role of p16 in OSF, epithelial dysplasia and OSCC as an 
early marker for malignant transformation and its liability in OSCC. 
AIM: 
 To study the expression of p16 in normal mucosa (Group I), OSF (Group 
II), epithelial dysplasia (Group III) and OSCC (Group IV). 
MATERIALS AND METHODS: 
 A total sample size of 70 which includes 10 controls of Group I, 20 cases 
of Group II, 20 cases of Group III, 20 cases of Group IV were studied for p16 
expression by immunohistochemistry.We have employed p16 monoclonal 
antibody of clone G175-405 in our study. The positive control sample of our study 
is squamous cell carcinoma of uterine cervix.  
RESULTS: 
 Out of 70 samples 16 cases (22.9%) of cases were p16 positive which 
includes five in group I, seven in group II, one in group III, three in group IV. Out 
of sixteen p16 positive samples four cases showed cytoplasmic staining (12,1 in 
Group I,II,IV respectively) , eleven cases showed nuclear and cytoplasmic 
staining (3,5,1,2 in Group I,II,III,IV respectively) and one showed cytoplasmic 
and membrane staining.  
CONCLUSION: 
 In this study we addressed the association particularly between p16 and 
OSF, epithelial dysplasia and OSCC. The results of this study with respect to OSF 
data, highlights that p16 could play a role in malignant transformation of OSF and 
we hypothesize that it could be associated with HPV.Further studies should 
ascertain the HPV status of the cases to be included, with a larger sample size to 
establish and understand if p16 expression could have a role in oral potentially 
malignant lesions and OSCC.  
KEYWORDS - p16, OSF, OSCC, Epithelial Dysplasia 
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INTRODUCTION 
 
Oral squamous cell carcinoma (OSCC), is the sixth most common cancer 
worldwide and the third most common form of cancer in the developing countries. 
Squamous cell carcinoma occurs due to multiple genetic changes leading to 
formation of either abnormal proteins or altered amount of normal proteins
1
.  
 
Clinical OSCC is often preceded by stepwise transition from potentially 
malignant states like leukoplakia and Oral Submucous Fibrosis (OSF) to the 
metastatic tumour phenotype. A variety of alterations accumulate to potentiate this 
transition to malignancy
2
. 
 
Leukoplakia, the most common potentially malignant lesion of the oral 
mucosa is defined by WHO as “a white patch or plaque that cannot be 
characterized clinically or pathologically as any other disease”. The malignant 
transformation rate for leukoplakia ranges from 5-20% and is particularly 
correlated with the degree of dysplasia
3
. The transition from normal oral 
epithelium to oral dysplasia and cancer results from accumulated genetic and 
epigenetic alterations
4
. The grading of epithelial dysplasia remains subjective as it 
relies on cellular atypia and architectural disturbances. 
 
OSF is an insidious, chronic disease affecting any part of the oral cavity 
and sometimes the pharynx. Although occasionally preceded by and/or associated 
with vesicle formation, it is always associated with a juxta-epithelial inflammatory 
reaction followed by a fibroelastic change of the lamina propria, with epithelial 
atrophy leading to stiffness of the oral mucosa and causing trismus and inability to 
eat
5
. 
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Given this aggressive nature of the potentially malignant lesions, 
identification of a suitable biomarker is imperative for timely diagnosis, prognosis 
and treatment
6
. Mutations in tumour suppressor genes namely p53, pRb, p16 and 
pro-apoptotic genes namely bcl2, bax have been variously attributed to the 
development and transformation of precancer to cancer. It has been found that 
inactivation of p16 occurs early in the development of OSCC
7
. 
 
Homozygous deletion, point mutation, loss of  heterozygosity and the 
more common aberrant methylation are the frequently reported alterations in the 
p16 gene
8
. p16 is a cyclin dependent kinase inhibitor(CKI), a tumour suppressor 
gene, and is the second commonly affected gene next to p53 in OSCC. The main 
function of p16 is to control the phosphorylation of retinoblastoma (Rb) gene and 
block the progression of cell cycle.  
 
Human papilloma virus (HPV) has been reported to initiate carcinogenesis 
in cervical cancers and OSCC. HPV causes oral carcinogenesis by acting on viral 
oncoproteins E6 and E7. P16 inactivates RB protein
67
. Similarly overexpression of 
p16 in cervical cancer is due to functional inactivation of Rb by HPV E7 
oncoprotein. Thereby, it clearly shows that HPV causes inactivation of p16 
pathway which leads to malignant transformation and carcinogenesis. There is a 
strong association between HPV presence and p16 in certain neoplasms. 
 
In this study, we wanted to ascertain the immunohistochemical expression 
of p16 in leukoplakia, OSF, OSCC and compare it with its expression in normal 
mucosa. We also included cases which were suggestive of HPV infection 
histopathologically, to ascertain its association. 
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AIM AND OBJECTIVES 
 
AIM: 
To assess the expression of p16 in normal oral mucosa, potentially 
malignant disorders (Leukoplakia, OSF) and OSCC. 
 
OBJECTIVES: 
1. To study the expression of p16 in formalin fixed paraffin embedded tissue 
specimens of normal oral mucosa by immunohistochemistry (IHC).  
2. To study the expression of p16 in formalin fixed paraffin embedded tissue 
specimens of epithelial dysplasia (Leukoplakia) by IHC. 
3. To study the expression of p16 in formalin fixed paraffin embedded tissue 
specimens of OSF by IHC. 
4. To study the expression of p16 in formalin fixed paraffin embedded tissue 
specimens of OSCC by IHC. 
5. To compare the expression of p16 between normal oral mucosa, 
Leukoplakia, OSF and OSCC. 
 
STUDY SETTING: 
The study was conducted in Department of Oral and Maxillofacial 
Pathology, Ragas Dental College and Hospital, Chennai, using formalin fixed 
paraffin embedded tissues. It is a retrospective study done to evaluate the 
expression of p16 in normal mucosa, OSF, leukoplakia, OSCC and normal 
mucosa using immunohistochemistry in formalin fixed, paraffin embedded tissue 
4 
 
specimens. The approval from Institutional Review Board (IRB) of Ragas Dental 
College and Hospital, Chennai was obtained. (ANNEXURE I) 
 
HYPOTHESIS: (NULL) 
There is no difference in expression of p16 in potentially malignant 
disorders (Leukoplakia, OSF), OSCC when compared to normal oral mucosa. 
 
STUDY SUBJECTS: 
The study material comprised of 70 formalin fixed, paraffin embedded 
tissue specimens. The samples were divided into 4 groups namely: Group I, Group 
II, Group III and Group IV. 
 
Group I: 10 normal mucosa tissue specimens.  
Group II: 20 histopathologically confirmed OSF fibrosis tissue  
       specimens.  
Group III: 20 histopathologically confirmed epithelial dysplasia  
(Leukoplakia) tissue specimens. 
Group IV:  20 histopathologically confirmed OSCC tissue  
specimens. 
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METHODOLOGY 
 
1. Tissue samples of Normal mucosa (n=10), OSF (n=20), Leukoplakia 
(n=20) and OSCC (n=20) were taken from the patients and from the 
archival blocks. 
2. A detailed case history including age, gender and occupation, past medical 
history & past dental history, history of drugs and trauma were recorded. 
3. General examination and intra oral examination was done. 
4. Biopsy was done from the lesion site. Normal mucosa was taken when the 
patients were undergoing minor surgery for impacted teeth cases. 
5. The tissue biopsied was immediately transferred to 10 % buffered 
formalin. 
6. After adequate fixation, tissues were embedded in paraffin. 
7. From the paraffin embedded blocks 4 microns thick, sections were cut and 
used for routine Hematoxylin and Eosin (H&E) staining and 
immunohistochemical (IHC) staining. 
8. Tissue sections of squamous cell carcinoma of cervix were used as 
positive controls for p16 positivity.  
 
HEMATOXYLIN & EOSIN (H&E) STAINING: 
REAGENTS: 
Harris’s hematoxylin  
1% acid alcohol 
Eosin 
 
 
6 
 
PROCEDURE: 
The slides were dewaxed in xylene and hydrated through graded alcohol to 
water. The sections on the slides were flooded with Harris’s hematoxylin for 5 
minutes. The slides were washed in running tap water for 5 minutes. The slides 
were differentiated in 1% acid alcohol for 5 minutes. 
 
The slides were washed well in running tap water for 5 minutes. The tissue 
sections on the slides were then stained in eosin for 30 seconds. The slides were 
washed in running tap water for 1 minute. The slides were then dehydrated 
through alcohol, cleared, mounted and viewed under light microscope (LM). 
 
IHC: 
ARMAMENTARIUM: 
 Microtome  
 Autoclave 
 Hot air oven 
 Slide warmer 
 Couplin jars 
 Measuring jar 
 Weighing machine 
 APES coated slides 
 Slide carrier 
 Aluminium foil 
 Micro-pipettes 
 Toothed forceps 
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 Electronic timer 
 Beakers 
 Rectangular steel tray with glass rods 
 Sterile gauze 
 Cover-slips 
 Light microscope 
 
REAGENTS USED: 
 Concentrated  HCl 
 Laxbro solution 
 APES (3 amino propyl tri ethoxy silane) 
 Acetone 
 Citrate buffer 
 Phosphate Buffer Saline (PBS) 
 3% H2O2 
 Deionized distilled water 
 Absolute alcohol 
 Xylene 
 
ANTIBODIES USED: 
1. Primary antibody –  p16 monoclonal antibody, BIOGENEXTM Clone: 
G175 – 405 
(FIGURE:1) 
2. Secondary antibody – Biogenex-super sensitive IHC detection system 
kit
TM
 (Poly Horse Radish Peroxidase - pretitrated anti-species 
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immunoglobulins labelled with enzyme polymer, super enhancer reagent, 
antimouse monoclonal negative control serum, and liquid DAB Diamino-
benzidine-chromogen) (FIGURE: 1) 
 
IHC PROCEDURE: 
PRETREATMENT OF THE SLIDES: 
 The slides were first washed in tap water for few minutes.  
 The slides were then soaked in detergent solution for 1 hour. 
 After 1 hour, each slide was brushed individually using the detergent 
solution and were transferred to distilled water.  
 The slides were washed in two changes of distilled water. 
 The slides were washed in autoclaved distilled water. 
 The slides were immersed in 1 N HCL (100 ml HCl in 900 ml distilled 
water) overnight. 
 The following day slides were taken out of acid and washed in two 
changes of autoclaved distilled water. 
 All the slides were then transferred to slide trays, wrapped in aluminium 
foil and baked in hot air oven for 4 hours at 180 degrees Centigrade. 
 
APES (3 Amino propyl tri ethoxy silane) coating: 
Slides first dipped in couplin jar containing acetone for 2 minutes 
↓ 
Dipped in APES for 5 minutes 
↓ 
Dipped in two changes of distilled water for 2 minutes each 
↓ 
Slides left to dry 
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PREPARATION OF PARAFFIN SECTIONS: 
After the slides were dry, tissue section of 5 micron thickness were made 
in a rotary manual microtome. The ribbons of tissue section were transferred onto 
the APES coated slide from the tissue float bath such that two tissue bits come on 
to the slide with a gap in between. One of the tissue sections was labelled positive 
(P) and the other negative (N). 
 
PROCEDURE: 
The slides with tissue sections were treated with three changes of xylene to 
remove paraffin wax. They were put in descending grades of alcohol and then 
rehydrated with water. Slides were then treated with 3% hydrogen peroxide for 30 
minutes to quench endogenous peroxidase activity of cells that would otherwise 
result in non – specific staining. The slides were then transferred to citrate buffer 
and autoclaved for antigen retrieval at 15 lbs pressure for 30 minutes. The slides 
were dipped in 3 changes of distilled water for 5 minutes each. Circles were 
drawn around the tissues, so that the antibodies added later on do not spread and 
are restricted to the circle. The tissues were incubated in protein blocking serum 
for one hour in an enclosed hydrated container. Then the slides were wiped 
carefully without touching the tissue section to remove excess of blocking serum. 
The primary antibody, p16 monoclonal antibody was added to P tissue on the slide 
and then to the N, PBS was added. The slides were incubated for one hour. Then 
the slides were wiped carefully without touching the tissue section to remove 
excess of antibody and washed with three changes of cold PBS for 5 minutes. 
Then a drop of ENVISION
TM
 horseradish peroxidase was added on both the 
sections and the slides were incubated for 30 minutes. Later slides were washed in 
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three changes of cold PBS for 5 minutes in each. The sections were washed in 3 
changes of cold PBS for 5 minutes in each. Then the slides were wiped carefully 
without touching the tissue section to remove excess PBS. Then a drop of DAB 
was added to the sections for 5 minutes. Slides were then washed in distilled water 
to remove excess chromogen and counter stained with hematoxylin. Then the 
slides were transferred to 70% alcohol, 100% alcohol and one change of xylene. 
The tissue sections were mounted with DPX. The slides were then observed under 
the microscope. Throughout the procedure care was taken not to dry the tissues. 
 
IHC PROCEDURE FLOW CHART: 
APES coated slides with 2 paraffin embedded tissues 
↓ 
Placed in xylene thrice (5 minutes each) 
↓ 
Placed in 100% isopropanol (5 minutes) 
↓ 
Placed in 70% isopropanol (5 minutes) 
↓ 
Washed in distilled water thrice (5 minutes each) 
↓ 
Placed in 3% hydrogen peroxide (20 minutes) 
↓ 
Kept in citrate buffer at pH 6 and autoclaved for antigen retrieval and bench 
cooled for 40 minutes 
↓ 
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Washed in distilled water thrice (5 minutes) 
↓ 
Protein blocking serum added and incubated for one hour 
↓ 
Primary antibody added to the specimen and incubated for one hour 
↓ 
Washed in PBS thrice (5 minutes each) 
↓ 
Secondary antibody added and incubated in an enclosed hydrated container (30 
minutes) 
↓ 
Washed in PBS thrice (5 minutes each) 
↓ 
HRP secondary reagent added and incubated (30 minutes) 
↓ 
Washed in PBS thrice (5 minutes each) 
↓ 
DAB added and incubated in an enclosed hydrated container (5 minutes) 
↓ 
Washed in PBS thrice (5 minutes each) 
↓ 
Stained with hematoxylin (20 seconds) 
↓ 
Washed in tap water 
↓ 
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Placed in 70% isopropanol (1minute) 
↓ 
Placed in 90% isopropanol (1minute) 
↓ 
Placed in 100% isopropanol (1 minute) 
↓ 
Placed in xylene (1 dip) 
↓ 
Slides were mounted using DPX 
↓ 
Slides were observed under the Light Microscope and graded 
 
Criteria for detecting the expression of p16: 
1. H&E sections: 
- The H&E stained sections were thoroughly examined. 
- Dysplastic lesions were categorised as mild dysplasia, moderate dysplasia and 
severe dysplasia. The koilocytic changes were also noted in dysplastic 
sections. 
- Oral squamous cell carcinoma was graded as well differentiated, moderately 
differentiated, poorly differentiated.  
2. Corresponding sections as examined by H&E were stained by IHC to detect p16 
expression. 
3. To all these sections the p16 antibody and the phosphate buffer saline was added 
based on the IHC protocol for the p16 antibody. 
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4. For IHC 
- The positive control used for IHC was squamous cell carcinoma of cervix. 
- The stained slides were screened, examined systematically for p16 expression 
in the nucleus, cytoplasm and also for membrane staining.  
- Positive cells were counted in the basal, suprabasal layers of normal mucosa. 
- Positive cells were counted in the basal, suprabasal layers in dysplasia, basal 
and suprabasal layers in oral submucous fibrosis, in the invasive front of oral 
squamous cell carcinoma. 
- Percentage of positive cells were also counted in each case and it was 
categorised as  
0 = negative; 1+ = 1% to 25% of cells positive; 2+ = 26% to 50%; 3+ = 51% 
to 75%; 4+ = 76% to 100%. 
- Connective tissue was also examined in all the lesions. 
- Nuclear staining was expressed as percentage of cells and the positivity were 
noted as mean labelling index (MLI) and cytoplasmic staining was also 
recorded. 
- 0, 1+, 2+, 3+, 4+ staining with reference to the positive control was observed 
with reference to nuclear and cytoplasmic staining grading. 
- The MLI for all the positive groups were calculated using the formula:  
Number of positive cells    
     X 100 
 Total number of cells 
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STATISTICAL ANALYSIS: 
Statistical analysis was done using SPSS
TM
 version 17. Proportion of p16 
staining was compared between and within the study groups using 'chi square' test. 
't' test and 'oneway ANOVA' was done for continuous variables. A p value of 0.05 
was considered statistically significant.  
 
SAMPLE SIZE: 
 To study the difference in expression of p16 between normal mucosa, OSF, 
epithelial dysplasia, OSCC a total of 70 cases were studied (10 normal mucosa, 20 
OSF, 20 epithelial dysplasia and 20 OSCC) with a power of 80% and at 5% 
significance level.  
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REVIEW OF LITERATURE 
 
CELL CYCLE: 
 The basic cell cycle is divided into four stages: G1, S, G2, and M. G1 is 
the gap phase during which cells prepare for the process of DNA replication. It is 
during the 'G1' phase that the cell integrates mitogenic and growth inhibitory 
signals and then decides to pause, or exit the cell cycle. An important checkpoint 
in 'G1' has been identified in which the cell becomes committed to DNA 
replication and completes a cycle. 'S' phase is defined as the stage in which DNA 
synthesis occurs. 'G2' is the second gap phase during which the cell prepares for 
the process of division. M stands for mitosis, the phase in which the replicated 
chromosomes are segregated into separate nuclei and cytokinesis occurs to form 
two daughter cells. In addition to G1, S, G2, and M, the term G0 is used to 
describe cells that have exited the cell cycle and become quiescent
9
.  
 
CDK INHIBITORS: INK4 and Cip/Kip FAMILY: 
Cyclin Dependent Kinase inhibitor proteins serve as an important 
mechanism during cell cycle, by preventing the premature entry of the cell into the 
S phase. This is brought about by binding of cyclin dependent kinase inhibitors 
(CKIs) to cyclin dependent kinases (CDKs) and thus inactivating CDKs activity, 
leading to a negative regulation of the cell cycle. The CDK activity is regulated by 
two families of inhibitors. The first family of CKIs are the Inhibitors of CDK4 
(INK4) proteins which include INK4A, INK4B, INK4C and INK4D. The second 
family includes the Cip and Kip family which are CDK inhibitory protein/ Kinase 
inhibitor proteins (Cip/Kip) family in mammals. This family is composed of 
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p21Cip1, p27Kip1 and p57Kip2. The CKIs function as a break for the premature 
entry of the cell to the S phase by inhibiting the CDKs
10
.
 
 
INK4/ARF LOCUS AND p16INK4a: 
The INK4 gene family encodes for p16INK4a, p15INK4B, p18INK4C, 
and p19INK4D, all of which bind to CDK4 and CDK6 and inhibit their kinase 
activities by interfering with their association with D-type cyclins. Specific 
polypeptide inhibitors of CDK4 and CDK6, so-called the INK4 proteins 
(inhibitors of CDK4), can directly block cyclin D-dependent kinase activity and 
cause G1 phase arrest. 
 
The INK4/ARF locus encodes three tumour suppressors, p15INK4B, 
p16INK4a and p19ARF. p16INK4a has been given different names (CDKN2A 
p16INK4a, CDK4I, MTS1, and p16). The gene is composed of 3 exons, with one 
alternatively spliced exon (El-f.). In humans it is situated on chromosome 9p21. 
pl6CDKN2A  protein encodes a 156 amino acid, 16kD cell cycle inhibitor protein, 
which normally blocks abnormal cell growth and proliferation by binding to 
complexes of cyclin-dependent kinases 4 and 6, and cyclin D. p16INK4a and 
p19ARF are transcribed using alternative exons 1α and 1β and spliced onto the 
same exons  but in different open reading frames. Despite overlapping coding 
regions, p16INK4a and p19ARF have unrelated amino acid sequences and distinct 
functions. Both p16INK4a and p19ARF are able to inhibit the cell cycle 
progression and are therefore referred to as tumour suppressors. p16INK4a 
regulates the cell cycle by inhibiting the CDK4 or CDK6 cyclin dependent 
kinases. Inhibition of CDK4 or CDK6 prevents the phosphorylation of pRb 
17 
 
proteins and progression into the S phase. pRb is a key gatekeeper in cell cycle 
transition. In normal cycling cells, entry to the S-phase from G1 phase is related to 
the functional inactivation of pRb by phosphorylation by cyclin dependent 
kinases
11
.
 
 
INK4A/ARF locus encodes two distinct products. Exon1α encodes part of 
p16INK4a protein which is a cyclin dependent kinase inhibitor. Exon1β is spliced 
onto an acceptor site common to 1α but encodes a nonhomologous protein called 
p19ARF, in an alternative reading frame. p16INK4a inhibits the CDK 4 and 6 
thus causing inhibition of E2F transcription factors.  INK4A/ARF locus encodes 
two distinct proteins functioning upstream of both Rb and p53 pathways in the 
cell. The INK4A/ARF locus represents a unique phenomenon by encoding two 
distinct tumour suppressor proteins inhibiting the cell cycle progression in a 
different manner. p16INK4a acts by inhibiting CDK4 and 6 and keeping pRb 
active while p19ARF leads to stabilization of p53. Functions of these proteins 
upstream of both pRb and p53 make this locus a ‘keystone gene’ in cell cycle12. 
 
p16 AND CARCINOGENESIS: 
The CDKN2A gene locus or the INK4a/ARF locus encodes two protein 
products; the p16/INK4a CKI, which blocks cyclin D/CDK2-mediated 
phosphorylation of Rb, keeping the Rb checkpoint in place. The second gene 
product, p14ARF, activates the p53 pathway by inhibiting MDM2 and preventing 
destruction of p53. Both protein products function as tumour suppressors and thus 
mutation or silencing of p16 locus impacts both the Rb and p53 pathways. p16 is 
crucial for the induction of senescence. Mutations at this locus have been detected 
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in oral cancer.  In some tumours, such as cervical cancer, p16INK4a is frequently 
silenced by hypermethylation of the gene. The other CKIs also function as tumour 
suppressors and are frequently mutated or otherwise silenced in many human 
malignancies, including familial melanomas, sporadic pancreatic 
adenocarcinomas, and squamous cell carcinomas of the esophagus
13
.  
  
Hypophosphorylated Rb in complex with the E2F transcription factors 
binds to DNA, recruits chromatin-remodeling factors (histone deacetylases and 
histone methyl transferases), and inhibits transcription of genes whose products 
are required for the S phase of the cell cycle. When Rb is phosphorylated by the 
cyclin D–CDK4, cyclin D–CDK6 and cyclin E–CDK2 complexes, it releases E2F. 
The latter then activates transcription of S-phase genes. The phosphorylation of 
Rb is inhibited by CKIs, because they inactivate cyclin-CDK complexes. Virtually 
all cancer cells show dysregulation of the G1-S checkpoint as a result of mutation 
in one of four genes that regulate the phosphorylation of Rb; these genes are Rb1, 
CDK4, the genes encoding cyclin D proteins, and CDKN2A(p16)
14
. 
  
Tsantoulis PK et al (2007) emphasized the importance of cancer 
transforming from the transitional precursor lesions. They also elucidated the 
genetic implications of the molecular mediators in cancer which includes cyclin 
dependent kinase inhibitors, TP53 and Rb1 and oncogenes like the cyclin family. 
They also summarised the tumorigenic effects of HPV and EBV
15
. 
  
Malumbres M et al (2005) reviewed the role of cyclin dependent kinases 
in cell proliferation. Based on their genetic study using mice, they proposed that 
CDK4 and CDK6 are not essential for organogenesis but are involved in the 
19 
 
generation of endocrine and hematopoietic cells. They found that CDK2 is 
important for the first meiotic division of male and female germ cells. These 
suggested that CDKs are important for the regulation of cell cycle and that they 
can be utilised for therapeutic strategies in cancer cells
16
. 
 
p16 GENE REGULATION AND INACTIVATION: 
Serrano M et al (1993) stated that the cell division of eukaryotic cells is 
regulated by a family of protein kinases which were latter classified as cyclin 
dependent kinases. The sequential activation of individual members of the family 
and their consequential phosphorylation of critical substrates promotes orderly 
progression through cell cycle. They concluded that p16INK4A acted at both the 
upstream and downstream function in the cell cycle of Rb to form a negative 
feedback loop which regulates the ability of Rb to prevent cell proliferation
17
.  
 
Tam SW et al (1994) studied the differential expression of p16 in 9 cases 
of 3 primary tissues namely; epithelium, muscles and nervous tissue wherein they 
found the differential expression of CKIs which played a key role in cell cycle 
regulation. They found that there was increase in levels of p16 along with 
functional inactivation of the retinoblastoma gene product. They also found that 
p16INK4a expression varies during the cell cycle peak during S phase. Their 
results showed a functional relationship between p16INK4A and the 
retinoblastoma gene product which indicates that p16INK4A is required for 
CDK4 inhibition only at the G1-S transition at the time when CDK4 kinase 
activity is not necessary
18
.  
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Mao L et al (1995) used cell lines derived from head and neck cancers, 
HeLA cell lines and normal lymphoblastic cells to investigate the presence of 
alternative promoter or initiator site showing methylation. p16INK4A AND 
p15INK4B were localized to chromosome 9p21, and pl6 was subsequently found 
to be mutated in familial melanoma and deleted in a wide variety of sporadic 
cancers. This finding emphasized the denovo methylation of 5' CpG island 
resulting in transcriptional block of full length p16 in many neoplasms
19
.  
 
Stone S et al (1995) studied the genomic structure and transcriptional 
regulation of p16 gene in humans by using genomic cloning, cDNA clones, in cell 
lines, lymphocytes by flow cytometry. From this two types of promoters α and β 
were found and were of similar size. These results showed p16 gene is complex 
with α and β promoters with different coding potential. They concluded that 
genetic evidence of p16 and Rb are members of growth regulatory pathway often 
inactivated leading to tumour progression. They also stated that if the role of β 
transcript is regulation of cell growth negatively, it could probably be another 
pathway that could be independent of p16 and Rb. They also used molecular 
genetic techniques to explore the role of p16 in normal development and cancer. 
They found that p16 derived mRNAs are probably generated from separate 
promoters and transcription from one of the promoters appears to be regulated, 
atleast in part, by the retinoblastoma gene product
20
.  
  
Beausejour CM et al (2003) proposed that telomere erosion and 
subsequent dysfunction limits the proliferation of normal human cells by a process 
termed replicative senescence. Replicative senescence is thought to suppress 
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tumorigenesis by establishing an essentially irreversible growth arrest that 
requires activities of the p53 and pRb tumour suppressor proteins. They showed 
that, depending on expression of the pRb regulator p16, replicative senescence is 
not necessarily irreversible. Expression of telomerase did not reverse the 
senescence arrest. Their results indicated that the senescence response to telomere 
dysfunction is reversible and is maintained primarily by p53. However, p16 
provides a dominant second barrier to the unlimited growth of human cells
21
.  
 
Ohtani N et al (2004) summarised the mechanisms involved in the 
senescence of p16 which leads to tumour suppression. They summarised the 
importance of telomere shortening which leads to senescence and telomere 
independent mechanisms which involves oxidative stress and inactivation of p16-
Rb pathway which leads to cancer
22
. 
 
p16 IN OTHER NEOPLASMS: 
 Herman J et al (1995) studied the promoter methylation of p16 in breast 
cancer, prostate cancer, renal cancer and colon cancer. They found aberrant 
denovo methylation of p16 in all the cancer cell lines. They concluded that p16 
promoter methylation plays an important diagnostic and prognostic factor for all 
the common human cancers
23
.  
 
Foulkes W et al (1997) reviewed the significance of p16 in different 
human neoplasms. They emphasized the presence of point mutations in familial 
atypical multiple mole/melanoma, pancreatic cancer and somatic mutations which 
includes homozygous deletions and CpG island methylations in different 
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carcinomas. They also signified the low frequency of p16 mutations in common 
tumours such as ovarian cancer, breast cancer and colon cancer
24
.  
 
p16 IN VASCULAR SMOOTH MUSCLE CELLS: 
Tanner F et al (2000) studied the expression of p27, p21 and p16 in 
vascular smooth muscle cells. Their results showed that p27 and p21 inhibits the 
proliferation of vascular smooth muscle cells while p16 has no interference in it. 
This suggested that p16 has no influence in growth of vascular smooth muscle 
cells
25
.  
 
p16 IN OESOPHAGEAL CANCERS: 
Mathew R et al (2001) studied the immunohistochemical expression of p5, 
pRb, p21, p16 to analyse the prognostic significance of these proteins and their 
alterations in the molecular basis of oesophageal cancers. They analysed 100 
oesophageal squamous cell carcinomas and found overexpression of p53, MDM2 
and cyclin D1 proteins in 73, 42 and 67% of the cases, respectively, and loss of 
expression of p21, p16 and pRb in 36, 45 and 75% of the cases, respectively. 
From the results, they concluded that p16 cannot be used as a specific marker for 
oesophageal cancer
26
.  
 
p16 IN CERVICAL CANCERS: 
Volgareva G et al (2004) studied the immunohistochemical expression of 
p16INK4a to determine the specificity of it in dysplastic and neoplastic cervical 
epithelium. They analysed 194 samples in total which included vaginal smears 
and biopsies. They found that p16INK4a is overexpressed in dysplastic and 
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neoplastic cervical epithelium and had a negative expression in normal tissues. 
Their results suggested that p16INK4a is reliable for early diagnosis of cervical 
neoplasm
27
.  
 
p16 IN ODONTOGENIC CYSTS: 
 Artese L et al (2008) studied the expression of p16 in different 
odontogenic cysts to correlate the clinical pathology of these cysts. Their results 
showed overexpression of p16 in radicular or follicular cysts and loss of 
expression in keratocystic odontogenic tumours. These differences suggested that 
aggressive potential of keratocystic odontogenic tumour may be related to 
decrease in p16 expression
28
.  
 
LEUKOPLAKIA: 
The term leukoplakia was coined by Schwimmer in 1877 to define a white 
lesion of the tongue. According to WHO, leukoplakia is a white patch or plaque 
that cannot be characterized clinically or pathologically as any other disease. 
Leukoplakia occurs mostly in middle-aged and older men. The most common sites 
are the buccal mucosa, alveolar mucosa, and lower lip. The lesions in the floor of 
mouth, lateral tongue, and lower lip also shows dysplastic or malignant changes. 
Early leukoplakia appears as a well defined slightly elevated grayish-white plaque 
or gradually blends into the surrounding normal mucosa. On progression of the 
lesion, it becomes thicker and whiter, and develops a leathery appearance with 
surface fissures (homogeneous or thick leukoplakia). Leukoplakias which develop 
surface irregularities are described as granular or nodular leukoplakias. Lesions 
developing a papillary surface are known as verrucous or verruciform leukoplakia. 
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Proliferative verrucous leukoplakia (PVL), is characterized by widespread, 
multiple sites of involvement, usually in patients without known risk factors
29
.  
 
MALIGNANT TRANSFORMATION OF EPITHELIAL DYSPLASIA: 
 Hall G et al (2008) studied the malignant transformation potential of 
epithelial dysplasia in 284 biopsies. They used pyrosequencing assays along with 
methylation specific PCR. They analysed 24 non transforming cases, 14 
transforming cases and 38 samples of epithelial dysplasia. Their results showed 57 
of the cases which transformed to oral squamous cell carcinoma showed p16 
promoter methylation and 2% of the cases which does not undergo malignant 
transformation were negative for p16 methylation. From their results they 
proposed that p16 can be used as a predictor for malignant transformation
30
.  
 
Wang Z et al (2009) studied the pathways of oral epithelial dysplasia 
transforming into a malignancy. They used two dimensional electrophoresis to 
study the proteins involved in the malignant transformation. From their results 
they found that varying levels of differentially expressed proteins were 
responsible for the malignant transformation. In particular three homologs of 
PA28 are significant in malignant transformation
31
.  
 
p16 IN EPITHELIAL DYSPLASIA: 
 Papadimitrakopoulou V et al (1997) found that the overexpression of the 
protein products of genes associated with the cell cycle tumour protein 53 (p53), 
CKI 2A and antigen identified by monoclonal antibody Ki-67 (Ki-67). They 
studied the overexpression of these factors in 76 leukoplakia biopsy specimens 
25 
 
and interpretable staining in 74 biopsy specimens and by direct sequencing 
analysis they found loss of heterozygosity in one specimen out of 10 biopsy 
specimens. The staining in dysplastic are mostly nuclear and cytoplasmic staining 
is not significant. They proposed that the loss of expression may be due to 3 
possible mechanisms. One mechanism is the use of only one marker to 
characterize the chromosomal region was not sufficient to detect a small deletion 
which may lead to the loss of protein expression. Second possibility is that normal 
contaminating DNA may cause retention pattern in cases of homozygous deletion. 
Third mechanism may be due to DNA methylation of p16INK4a causing loss of 
protein expression
7
.  
 
Bradley K et al (2006) showed immunohistochemical overexpression of 
p16 in dysplastic lesions of the oral cavity. The frequent occurrence of p16 
inactivation during early carcinogenesis has led to its investigation as a surrogate 
marker for dysplasia. They studied 119 biopsy specimens representing various 
oral cavity sites and degrees of dysplasia; showed 61/119 (51%) cases showed no 
p16 immunoreactivity, including 12/33 (36%) cases of non dysplastic mucosa, 
11/28 (39%) cases of mild dysplasia, and 38/58 (66%) cases of moderate/severe 
dysplasia. The remaining cases showed p16 expression limited to the basal and 
suprabasal nuclei and generally confined to the lower one-third of the epithelium. 
Based on the results which showed decreased expression of p16 in dysplastic 
lesions they concluded that p16 immunohistochemistry is not helpful in 
differentiating dysplastic from non dysplastic mucosa. They also concluded that 
downregulation of p16 contributed to cellular proliferation, resulting locally in a 
more advanced tumour. The decreased expression of p16 may be due to 
inactivation of p16
32
.  
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Angiero F et al (2008) studied the expression of the cell-cycle proteins p16 
and p53 in the dysplastic epithelium, in association with Ki-67 which may 
represent significant markers to recognize evolution of precancerous disease in the 
oral cavity and to improve identification of the degree of dysplasia. The nuclear 
expression of p53 and Ki- 67 and nuclear and/or cytoplasmic expression of p16 
protein was examined in 54 biopsy specimens from the oral cavity obtained over a 
period of 3 years. Results showed p53 and p16 expression respectively in 81.8% 
and 54.5% of cases, while Ki-67 was elevated in all the cases. The expression of 
the cell-cycle proteins p16 and p53 in the dysplastic epithelium, in association 
with Ki-67, may represent significant markers to recognize evolution of 
precancerous disease in the oral cavity and to improve identification of the degree 
of dysplasia
33
. 
  
Liu M et al (2010) reported that that promoter hypermethylation of key 
genes in critical pathways is common in head and neck squamous cell cancers 
(HNSCC), as well as in serum and saliva of patients with such cancers. p16INK4a 
is critical at the G1-S transition of the cell cycle, being responsible for maintaining 
Rb protein in its nonphosphorylated state. From the analysis of methylation 
specific polymerase chain reaction (PCR) in 111 patients who presented with oral 
leukoplakia they found that multiple epigenetic abnormalities have already 
occurred in oral premalignant lesions similar to early genetic alterations. They 
concluded that p16 promoter hypermethylation is present in most of the 
premalignant lesions and cancers as well
34
.  
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HPV IN EPITHELIAL DYSPLASIA: 
 Fregonesi PA et al (2003) studied about the presence of HPV in epithelial 
dysplasia, hyperplasia and squamous cell carcinoma by insitu hybridisation and 
immunohistochemistry in 46 oral biopsy specimens which were oral hyperplasias, 
Oral squamous papilloma, oral premalignant lesions, oral squamous cell 
carcinoma respectively. From their results they found that 18 of the 46 biopsy 
specimens were HPV positive and 28 were HPV negative. They proposed that p16 
protein expression in oral carcinogenesis may occur in relation to the functional 
inactivation of Rb protein by HPV infection. They also suggested that HPV 
pathogenesis by E6 and E7 oncoproteins deactivates Rb which thereby causes 
malfunction of p16. They concluded that there is a strong correlation between the 
presence of HPV and their overexpression in potentially malignant and malignant 
lesions of the oral mucosa
35
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Bouda M et al (2000) determined the role of HPV in oral carcinogenesis. 
They studied their presence in 53 potentially malignant and malignant oral lesions 
which includes 29 cases of hyperplasia, 5 cases of dysplasia, 19 cases of 
squamous cell carcinoma and 16 biopsies from healthy individuals using highly 
sensitive PCR, restriction fragment length polymorphism analysis, dot blotting 
and insitu hybridisation. They found that in all the different techniques used, at 
least one type of HPV which included HPV subtypes 16, 18, 33 and 58 were seen 
commonly. They concluded that there was an early involvement of HPV in oral 
carcinogenesis
36
.  
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ORAL SUBMUCOUS FIBROSIS: 
Pindborg et al (1966) proposed that OSF is an insidious, chronic disease 
affecting any part of the oral cavity and sometimes the pharynx. Although 
occasionally preceded by and/or associated with vesicle formation, it is always 
associated with a juxta-epithelial inflammatory reaction followed by a fibroelastic 
change of the lamina propria, with epithelial atrophy leading to stiffness of the 
oral mucosa and causing trismus and inability to eat. There are connective tissue 
changes present in OSF. 
 
The early stage is characterized by a finely fibrillar collagen, dispersed 
with marked edema. The fibroblastic response is produced by fibroblasts which 
are plump of young cells with abundant cytoplasm. In later stages, the collagen 
present in connective tissue is moderately hyalinized, the amorphous change 
starting from the juxta-epithelial basement membrane. Occasionally, thickened 
collagen bundles are still seen separated by slight residual edema. The fibroblastic 
response is less marked and the fibroblasts are mostly having elongated spindle-
shaped nuclei and scanty cytoplasm. Oral epithelium in the affected areas is 
markedly atrophic as compared with the thickness of normal oral epithelium. The 
rete pegs are completely lost. The buccal mucosa, normally non-keratinised are 
showing. The atrophy of the oral epithelium is probably secondary to the 
connective tissue changes
5
.  
 
PATHOGENESIS OF OSF: 
Thavarajah R, et al in 2004 conducted a cytological study of copper in 
OSF. They found that high copper content present in areca nut plays a vital role in 
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pathogenesis of OSF. This study evaluates the copper-staining pattern of buccal 
epithelial cells in oral cytological smears of non-chewers, chewers and OSF. 
Copper appeared as shades of pale red within the cytoplasm of chewers and did 
not show any stain in non-chewers. Intense red stain was seen in OSF smears as 
dark granules within the cytoplasm. They concluded that intense staining of 
copper in OSF buccal smears in areca nut chewers support the role of copper in 
the pathogenesis of OSF
37
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Tilakaratne WM et al (2006) reviewed the etiology and pathogenesis of 
OSF from data taken from recent epidemiological studies. The studies provided 
evidence that arecanut is the main aetiological factor for OSF. A dose-dependent 
relationship was observed for both frequency and duration of chewing arecanut 
(without tobacco) in the development of OSF. Commercially freeze dried products 
such as pan masala, Gutkha and mawa have high concentrates of arecanut per 
chew and appear to cause OSF more rapidly than by self-prepared conventional 
betel quid that contain smaller amounts of arecanut. The authors hypothesized that 
the increased collagen synthesis or reduced collagen degradation as possible 
mechanisms in the development of the disease. These chemicals appear to 
interfere with the molecular processes of deposition and/or degradation of 
extracellular matrix molecules such as collagen. In vitro studies on human 
fibroblasts using areca extracts or chemically purified arecoline support the theory 
of fibroblastic proliferation and increased collagen formation that is also 
demonstrable histologically in human OSF tissues
38
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MOLECULAR PATHOGENESIS OF OSF: 
 Initial events of the disease include chronic irritation of the oral mucosa 
due to constant betel quid chewing habit. This further leads to chronic 
inflammation. The normal physiologic events include activation of T cell and 
macrophages at the irritation site. Then there will be increase in cytokines IL6, 
TNF, IFα and increase in growth factor TGFβ. In normal physiologic process 
there will be constant production of collagen and degradation. In OSF there will 
be increase in collagen production and decrease in collagen degradation. In 
collagen production pathway TGFβ activates N procollagen peptides, procollagen 
precursor, procollagen genes. These in turn increase procollagen which further 
releases collagen in soluble and insoluble form. As a result there will be total 
increase in collagen production. In collagen degradation pathway TGFβ activates 
genes, tissue inhibitor of matrix metalloproteinase (TIMP) and plasminogen 
activator inhibitor (PAI). TIMP inhibits activated collagenase and PAI inhibits 
conversion of plasminogen into plasmin. Plasmin also inhibits conversion of 
procollagenase into collagenase as a result there will be decreased collagenase 
activity and collagen degradation. This leads to fibrosis of the oral mucosa and 
OSF results
39
.  
 
MALIGNANT TRANSFORMATION OF OSF: 
 Murti PR et al (1985) conducted a study in OSF affected individuals where 
66 patients with OSF were followed-up for a period of 17yr (median observation 
10 yr) in Ernakulam District, Kerala, India. Oral cancer developed in five (7.6%) 
patients. The malignant transformation rate in the same sample was 4.5% over a 
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15-yr observation period (median 8yrs). These findings impart a high degree of 
malignant potential of OSF
40
. 
 
Pillai R et al (1992) proposed that OSF is a condition with a high risk of 
malignant transformation. They suggested a multifactorial causation for the 
malignant transformation of OSF namely; genetic, carcinogenic, immunologic, 
viral, nutritional, and autoimmune possibilities, all of which also have been 
implicated in the development of oral cancer
41
. 
 
 
Jeng JH et al (2001) found that areca nut products induce mutagenic and 
genotoxic effects, in addition to inducing preneoplastic as well as neoplastic 
lesions in experimental animals. Areca nut should, thus, be highly suspected as a 
human carcinogen. The mutagenicity and genotoxicity of areca alkaloids has been 
detected by many short-term assays. It appears that areca nut toxicity is not 
completely due to its polyphenol, tannins and alkaloid content. Reactive oxygen 
species produced during auto-oxidation of areca nut polyphenols in the Betel Quid 
chewer's saliva, are crucial in the initiation and promotion of oral cancer. 
Nitrosation of areca alkaloids also produces areca nut-specific nitrosamines, that 
have been demonstrated to be mutagenic, genotoxic and are capable of inducing 
tumours in experimental animals
42
.  
 
Afroz N et al (2006) studied about the association between areca nut and 
malignant transformation of OSF. They concluded that arecoline in areca nut can 
induce fibroblast proliferation and collagen synthesis and may penetrate the oral 
mucosa to cause progressive cross linking of collagen. Tobacco chewing and 
smoking are not considered to play a role in the development of this disease
43
.
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Pundir S et al (2010) found the development of cancer from OSF in 2 
cases. In patients with OSF, the oral epithelium becomes atrophic and thereby 
becomes more vulnerable to carcinogens. It is now accepted that chewing areca is 
the most important aetiological factor for developing OSF. The atrophic 
epithelium shows first an intercellular edema and later epithelial atypia associated 
with moderate epithelial hyperplasia. From then on, carcinoma may develop any 
time. It is suggested that OSF should be regarded as a condition that causes 
predisposition to the development of oral cancer
44
. 
 
 
p16 IN OSF: 
 Takeshima M et al (2008) studied the occurrence of hypermethylation in 
OSF. They found high frequency hypermethylation of p14, p15 and p16 in OSF 
and no hypermethylation in normal epithelium. No significant correlation was 
observed between p53 positive reactions and hypermethylation in any lesions. The 
hypermethylation was highly detectable even in p53 negative lesions, suggesting 
that hypermethylation of p14, p15 and p16 occur regardless of whether the lesions 
have p53 mutations or not. From all these findings they concluded that 
hypermethylation may be involved in the pathogenesis of OSF
45
.  
  
Fung L et al (2010) investigated the expression of Fragile Histidine Triad 
(FHIT) and p16 protein in 44 cases of OSF and 15 cases of OSF concomitant with 
OSCC and 8 cases of normal mucosa for evaluating the carcinogenesis in OSF. 
Results showed p16 expression in normal tissues, OSF and OSF concomitant with 
oral squamous cell carcinoma 100%, 72.7% and 40% respectively. From these 
results they proposed that loss of p16 is likely to be an early occurrence in the 
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carcinogenesis of OSF and the positive correlation between FHIT and p16 
demonstrates that they may act together promoting the carcinogenesis of OSF
46
.  
 
ORAL SQUAMOUS CELL CARCINOMA: 
Williams HK et al (2000) postulated that OSCC, the most common cancer 
of the oral cavity accounts for over 90% of malignant neoplasms. The incidence of 
oral cancer remains high and is associated with many deaths in both Western and 
Asian countries. Several risk factors for the development of oral cancer are now 
well known, including smoking, drinking and consumption of smokeless tobacco 
products. Genetic predisposition to oral cancer has been found in certain cases but 
its components are not yet entirely clear. In accordance with the multi-step theory 
of carcinogenesis, the natural history of oral cancer seems to be gradually 
evolving through transitional precursor lesions from normal epithelium to a full-
blown metastatic phenotype. A number of genomic lesions accompany this 
transformation. Furthermore, several key genes have been implicated, especially 
well-known tumour suppressors like the cyclin-dependent kinase inhibitors, TP53 
and RB1 protein and oncogenes like the cyclin family, Epidermal Growth Factor 
Receptor (EGFR) and Rouse Avian Sarcoma (RAS). Viral infections, particularly 
with oncogenic HPV subtypes and Epstein Barr Virus (EBV), can have a 
tumorigenic effect on oral epithelia
47
. 
 
Patel V et al (2001) reviewed the various diagnostic tools used in the 
detection of OSCC to understanding the molecular basis of cancer. This included 
head and neck squamous cell carcinoma-specific chromosomal alterations 
c(CAP), systematic identification of novel genes using head and neck cancer 
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genome anatomy project (HN-CGAP), characterisation of malignant, potentially 
malignant and normal cells by means of DNA microarray technology using laser 
capture mirodissection (LCM) which plays a vital role in detection of head and 
neck squamous cell carcinomas and their pathogenesis
48
.  
 
Perez OB et al (2006) summarised the alterations in genetic basis and 
disease progression of squamous dysplasia to cancer. They discussed the loss of 
heterozygosity (LOH) of 9p21 chromosomal region in the early stages of cancer. 
They discussed the genetic alterations involving in inactivation of tumour 
suppressor genes viz. p16INK4a, p53, cyclin D1, p14
ARF
 and activation of proto-
oncogenes viz FHIT, Rb, EGFR and RASSF1A respectively
49
.  
 
Massano J et al (2006) reviewed the relevant published data into 3 groups 
patient-, tumour-, treatment related factors. Tumour related factors included some 
less commonly studied factors viz. disease staging, extracapsular dissemination, 
resection margin free of disease and tumour thickness. Tumour molecular factors 
included several genes which includes tumour suppressor genes p16 and p53, 
overexpression of oncogenes PRAD1, EGFR and cyclins and cyclin dependent 
kinases involved in the cell cycle. They concluded that large scale study of the 
factors involved in prognosis of cancer must be done to evaluate the therapeutic 
strategies of cancer
50
. 
 
Scully C et al (2008) summarised the current diagnostic tools for detection 
of oral cancer which included biopsy and histopathological examination, vital 
staining, biomarkers, brush biopsy, DNA ploidy, optical systems and saliva-based 
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oral cancer diagnostics. They suggested certain other diagnostic tools like laser 
and light induced fluorescence spectroscopy, photo acoustic imaging, quantum 
dots, narrow band imaging, 2 photon fluorescence, tetrahertz imaging for the 
detection of oral cancer. They proposed that along with well-established imaging 
techniques other adjunct detection methods must be used to evaluate the early 
diagnosis and treatment of cancer
51
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Campo TJ et al (2008) summarised the importance of cytogenetic 
alterations which included LOH, microsatellite instability, epigenetic alterations 
like aberrant methylation of chromosomes involving cancer and precancer. They 
proposed that p16 methylation and mutation involves in 70% of head and neck 
squamous cell carcinomas. They also stated that the tumour-stroma interactions 
and the intercellular signalling pathways were involved in OSCC adding that 
signalling molecules, stromelysin, E-cadherin, oncogenes, tumour suppressor 
genes and viruses were responsible for tumorigenesis
52
.  
 
p16 IN ORAL SQUAMOUS CELL CARCINOMA: 
 Reed AL et al (1996) studied the expression of p16 in head and neck 
squamous cell carcinomas using immunohistochemistry and compared with 
microsatellite analysis, southern blot analysis and sequence analysis. They used 29 
head and neck squamous cell carcinomas and the results showed loss of p16 
expression in all 29 cases in immunohistochemistry. By other analysis, 
homozygous deletions and methylations were found in 24 cases of OSCC. From 
their results they concluded that there was higher frequency of p16inactivation in 
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squamous cell carcinomas and the inactivation may be due to homozygous 
deletions, point mutations and methylation of CpG islands
8
. 
 
Lazarus P et al (1998) studied the genetic mutations of p16 and p53 in oral 
squamous cell carcinomas and their association with specific genotypes using 
PCR. They found mutations in p53 exons 5-9 and p16 exons1-2 mutations. They 
found significant association of p53 with genotypes CYP1A1 and GSTM1 and no 
association of p16 with these genotypes. They concluded that mutations of these 
genes may be due to specific carcinogens and their association with specific 
genotypes which helps in the prognosis
53
.  
 
Sartor M et al (1999) studied the expression of cyclin D1, p16, Rb in 
OSCC cell lines using PCR. They did their study in 26 OSCC, nine premalignant 
lesions, three normal oral tissue samples and eight established OSCC cell lines for 
mutations in the p16/MTS1 gene. They found p16/MTS1 gene alterations in 5/26 
(19%) primary tumours and 6/8 (75%) cell lines. They found that there is absence 
of p16/MTS1 expression in 18/26 (69%) OSCC, 7/9 (78%) premalignant lesions 
and 8/8 cell lines using western blot. Their data showed that p16/MTS1 mutations 
and loss of expression is common in oral cancer cell lines and less frequent in 
primary OSCC tumours. They found a different pattern of p16/MTS1 mutations in 
OSCC compared to other cancers with all the detected p16/MTS1 mutations 
resulting in premature termination codons or a frameshift. The RB protein 
expression in about half (44%) of OSCCs is inversely correlated with p16/MTS1 
expression. They found genetic alterations which included LOH, CpG island 
aberrant methylation in most of the cancer cell lines
54
.  
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Poi MJ et al (2001) studied the somatic mutations of INK4a-ARF locus in 
squamous cell carcinomas of head and neck which includes samples from 
pharynx, larynx, oral cavity and unclassified samples. They used PCR 
nonradioactive modification of single stranded conformational polymorphism 
(SSCP) termed cold SSCP in 100 squamous cell carcinomas. They found 
microdeletions, insertions, sequence alterations in 27 cases of squamous cell 
carcinoma in all the analysis. They found that many microdeletions and 
microinsertions are present along with the usual point mutations involved in p16 
in cancer. They also proposed that these genetic alterations should be studied in a 
large scale to evaluate the importance of p16 in cancer. From the results they 
concluded that alterations in p16 and p14 resulted in complete mutation of INK4a-
ARF locus which is prevalent in the squamous cell carcinoma of head and neck
55
.  
 
Yuen PW et al (2002) studied p16 expression in 225 squamous cell 
carcinoma using immunohistochemistry. They found decreased expression in 48% 
of the cases and more intense expression in tumours with aggressive nature. The 
expression of p16 gradually reduced as the staging of the tumour advanced. They 
proposed that p16 is not significantly related to sex, age but being an important 
factor in cell cycle its reduced expression in tumours with high rate of 
proliferation is obvious. They concluded that from their data p16 cannot be used 
as a prognostic factor and for detecting nodal metastasis and survival
56
.  
 
Geisler SA et al (2002) did a cohort study for the expression of p16 and 
p53 in 171 cases of squamous cell carcinomas under treatment. They found 
increased expression of p53 in majority of the cases. The cases expressing 
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alterations in both p16 and p53 were of no diagnostic importance. They concluded 
that p16 cannot be used as a prognostic indicator for survival and recurrence of 
cancer
57
.  
 
Viswanathan M et al (2003) studied promoter hypermethylation of p16, 
p15, hMLH1, MGMT and E-Cadherin in 51 oral squamous cell carcinomas using 
sensitive restriction-multiplex PCR method. They found aberrant methylation of 
atleast one gene in 75% of the cases and no methylation was observed in 25 oral 
squamous tissues. They proposed that the methylation may be due to somatic 
sequence alterations in the genes. They also emphasised the importance of 
methylation in cancers. The methylation in human cancer is distinct and need not 
be in the same region on subsequent formation. Particularly in p16, there is higher 
incidence of methylation in the promoter site of the gene which gives more 
information regarding the significance of p16. They concluded that detection of 
promoter methylation of any of these genes may help in the diagnosis of OSCC
58
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Ai L et al (2003) studied the p16 expression in 100 squamous cell 
carcinomas using immunohistochemistry, methylation specific PCR. They found 
74% of cases showing p16 promoter methylation and 26% of cases showing loss 
of expression. They found that the epigenetic mechanism which causes 
methylation of p16 in OSCC is absent in case of lung cancer as found in earlier 
reports. Most of the cases from their study did not show any promoter methylation 
instead they revealed mutational changes which includes homogeneous deletions 
in common. From their results they concluded that p16 can be used as a predictive 
and prognostic factor for head and neck squamous cell carcinoma
59
.  
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 Nilsson K et al (2004) studied about the staining patterns and 
characterized the expression of p16INK4a, Rb-phosphorylation and proliferation 
in actinic keratosis, squamous cell carcinoma in situ and invasive squamous cell 
carcinoma based on the infiltrative behaviour. From their results they showed the 
expression of p16INK4a were  weak and cytoplasmic p16INK4a staining and 
functional Rb in actinic keratosis, Strong nuclear and cytoplasmic staining in all 
carcinomas in situ in parallel with inactive Rb, invasive squamous carcinoma with 
a mixed p16 staining pattern where some tumours had strong cytoplasmic 
staining, large fraction of Rb-phosphorylated cells and high proliferation. They 
highlighted the upregulation of cytoplasmic p16INK4a in infiltrative cells 
compared to tumour cells. Similarly a strong and combined nuclear and 
cytoplasmic staining in infiltrative cells, was present in other invasive squamous 
cancers. They proposed that there is an independent potential behaviour of p16 to 
infiltrate or upregulate into the cytoplasm or nucleus which is also independent of 
tissue localisation or potential to affect proliferation
60
.  
 
Weinberger PM et al (2004) studied the expression of p16 in 123 
oropharyngeal squamous cell cancer using immunohistochemistry. They found 
both overexpression of p16 in advanced stage and metastasising cancer cell lines 
and in local recurrences and loss of expression. They suggested that 
overexpression may be related to poor survival rate and the loss of expression may 
be related to prognosis and disease free survival.  From their findings they 
proposed that p16 is a significant prognostic factor for and in local recurrences
61
.  
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Lee JK et al (2004) analysed inactivation patterns of p16INK4a genes to 
evaluate the role of p16INK4a inactivation in the development of oral squamous 
cell carcinoma in 6 different cell lines. 3 kinds of inactivation pattern were 
examined (by homozygous deletion, promoter hypermethylation, point mutation). 
They used methylation specific PCR for their analysis. Their study concluded that 
inactivation patterns of p16INK4a were mainly homozygous deletion, promoter 
hypermethylation rather than point mutation in oral cancer cell lines. They also 
suggested that the therapeutic modalities of oral squamous cell carcinoma should 
be focussed on the type of inactivation
62
.  
 
 Muirhead DM et al (2006) studied the p16 and retinoblastoma (Rb) gene 
expression in patient with 39 squamous cell carcinomas with resected margins 
using immunohistochemistry. They found retinoblastoma expression in 39 cases 
and p16 expression was seen in 6 cases. They found that there is no correlation 
between anatomic site and p16 changes instead they proposed that most of the oral 
premalignant lesion with reduced p16 expression is due to loss of heterozygosity. 
They proposed that reduced expression was seen in cases of nonkeratinised areas, 
poorly differentiated morphology and Rb gene expression in keratinised areas. 
They concluded that p16 and Rb expression were related to morphological 
findings and presence of keratinisation. They also proposed that changes in p16 
also attribute to histologic grading and metastatic potential of the tumour cells
63
.  
  
Vairaktaris E et al (2007) studied the expression of p16 in oral squamous 
cell carcinoma, dysplastic and hyperplastic epithelium. They did their study in 37 
animals which were taken as controls and 3 experimental groups in which they 
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induced carcinogenesis and sacrificed at 10, 14, 19 weeks. They tumour sections 
under histopathologic study showed decreased expression of p16 in hyperplasia, 
dysplasia and cancer in decreasing order. They proposed that increased amount of 
p16 protein during hyperplasia observed may be due to unscheduled 
transactivation of the p16 gene. Increased accumulation of p16 mRNA and protein 
is attributed to cellular senescence, oncogenic hyperactivity of RAS and 
inactivation of Rb. They concluded that p16 can be used as a prognostic indicator 
for cancer
64
.  
  
Dragomir LP et al (2012) studied the p53, p16 and Ki67 expression in 34 
squamous cell carcinomas and dysplastic lesions using immunohistochemistry. 
Their results showed increased expression of Ki67 in all the cases, increased 
expression of p16 in dysplastic lesions and increased expression of p53 in tumour 
front of the dysplastic lesions. They suggested that p16 expression was mainly due 
to histopathologic prognostic factors. They concluded that these genes can be used 
as a marker for detecting the aggressive nature of the lesions
65
.  
 
HPV IN ORAL SQUAMOUS CELL CARCINOMA: 
 Hafkamp HC et al (2003) studied HPV association in premalignant 
lesions, head and neck squamous cell carcinomas, metastasising primary 
carcinomas using FISH, immunohistochemistry and SSCP analysis. They found 
HPV association and p16 expression in majority of the cases. They proposed that 
HPV association in head and neck tumours are attributed to the risk factor of 
tobacco and alcohol consumption. They also suggested that tonsils are usually 
prone to HPV, due to the easy accessibility of tonsil to HPV and its prompt 
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metaplastic capability as in uterine cervix, the presence of deep crypts and 
invaginations on its surface which facilitates the contact of HPV with the basal 
cells and lastly the immediate availability of cytokines from the underlying 
lymphocytes. They concluded that HPV plays an important role in head and neck 
tumorigenesis with or without use of tobacco and alcohol consumption
66
.  
 
Kreimer AR et al (2005) reviewed a series of cases to detect the HPV 
subtypes in the head and neck cancers. They did their study in 5,046 head and 
neck squamous cell carcinomas using PCR based detection methods and genotype 
determination. They found out that prevalence of HPV subtypes 16 and 18 was 
higher in oropharyngeal cancers and laryngeal cancers and in squamous cell 
carcinomas respectively in descending order. From the results they proposed that 
association of HPV in oropharyngeal cancers are much significant and needs 
further investigation for detailed prognostic factors
67
. 
 
Lewis JS et al (2010) studied the presence of HPV and p16 expression in 
squamous cell carcinomas using PCR and immunohistochemistry respectively. 
From their results they found the presence of HPV and p16 expression in most of 
the oropharyngeal squamous cell carcinomas. They proposed that there is a 
complete association of HPV in oropharyngeal cancers and p16 
immunohistochemistry and that this can be used as the best diagnostic criteria for 
oropharyngeal cancers
68
.  
 
Joseph AW et al (2011) reviewed the shifting trends in the incidence and 
mortality of HPV associated head and neck squamous cell carcinoma (HNSCC). 
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They reviewed the complete epidemiology of HPV associated HNSCC. They 
proposed that there is an increase in HPV-HNSCC in the tonsils and/or base of 
tongue. They also emphasized that HPV-HNSCCs are completely unique from 
cancers which are associated with the risk factors like tobacco- and alcohol-
related and shows a different tumour behaviour. They emphasized the importance 
of routine examination of HPV status in clinical setting which gives prognostic 
information and shows patients eligible for clinical trials for better treatment 
strategies
69
.  
  
O’Rorke MA et al (2012) conducted a metaanalysis of HPV association in 
head and neck cancer and their survival. They found reduction in mortality in 
HPV associated head and cancers compared to cancers not associated with HPV. 
They proposed that there was an increase in the association of HPV in head and 
neck cancers which gave way to detailed study in their molecular involvement
70
.  
  
Rautava J et al (2012) studied the prognostic significance of HPV 
associated head and neck cancers in 106 head and neck squamous cell carcinoma 
cases. HPV genotyping was done in all the cases. They also elucidated the 
presence of cofactors which also includes HPV subtypes 16, 18 and 
cytomegalovirus. They proposed that treatment outcomes of HPV associated head 
and neck cancers were comparatively poor. With the outcomes they also 
suggested that there is a strong association of HPV subtypes in head and neck 
cancers
71
.  
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Dufour X et al (2012) reviewed the complete epidemiology, pathogenesis 
and biomarkers for HPV associated head and neck cancers. They emphasized the 
importance of different biomarkers in detecting the early involvement of HPV 
subtypes in head and neck cancers. The most significant biomarkers for HPV are 
p16, p53, EGFR and Cyclin D1
72
.  
  
Isayeva T et al (2012) reviewed the treatment outcomes in HPV positive 
and negative oropharyngeal cancer. They also presented the data on HPv16/18 
transcriptional status in oral cavity carcinomas, salivary gland neoplasms using 
nested reverse transcription PCR. They detected HPV DNA in 4,195 oral cavity 
cancer patients, 1,712 laryngeal cancer patients, 120 sinonasal cancer patients, 154 
nasopharyngeal cancer patients. Their data revealed significant association of 
HPV in orolaryngeal neoplasm. From the results they proposed that there is a 
strong viral interaction with orolaryngeal tumours which leads to progression of 
carcinoma
73
. 
 
HPV and p16: 
 Konig F et al (2007) studied the presence of HPV expression in 60 head 
and neck squamous cell carcinomas using tissue microarrays and their presence 
using insitu hybridisation, HPV positive expression using immunohistochemistry. 
their results showed HPV positivity in 10 carcinomas, HPV protein expression in 
35 out of 60 carcinomas. From the results they showed statistically significant 
relationship between HPV and p16. Mutations of p16 has been found in cancers 
involving breast oesophagus, bladder tumours. From this study they have 
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proposed that HPV also may involve in the alterations in p16 gene which further 
leads to malignancy
74
.  
 
Kong CS et al (2009) studied the relationship between human papilloma 
viruses and head and neck squamous cell carcinomas to correlate the prognostic 
markers. They studied 82 squamous cell carcinomas by pyrosequencing analysis. 
They found that 44% of the tumours showed strong HPV positive signals. From 
their results they showed that there is a strong relationship between HPV and head 
and neck squamous cell carcinomas
75
.  
  
Chen ZW et al (2012) studied about the predictive findings of HPV based 
on equivocal p16 staining and percentage of positively stained cells. They did a 
retrospective study on cases which underwent p16 IHC and PCR. They studied a 
total of 392 cases which used p16 IHC and 26 cases which used p16 PCR. From 
these they studied 32 cases were studied for equivocal staining of p16 in IHC 
group and 15 cases in PCR group. Their results showed strong association of 
cytoplasmic and membrane staining with negative HPV status and faint, diffuse 
nuclear and cytoplasmic staining with positive HPV status. From their results they 
suggested that the staining pattern of p16 were commonly associated with HPV 
interaction
76
.  
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RESULTS 
SAMPLE CHARACTERISTICS: 
10 controls of normal mucosa (Group I), 20 cases of OSF (Grousp II), 20 
cases of leukoplakia (Group III) and 20 cases of oral squamous cell carcinoma 
(Group IV) were analysed for immunoreactivity of p16 protein. 
 
Distribution of Age among Total Study Groups: 
 The cases were divided into six groups based on age. The groups were 21- 
30 years, 31-40 years, 41-50 years, 51-60 years, 61-70 years and above 70. In 
Group I out of 10 cases 6(60%) belonged to 21-30 yerars, 3(30%) belonged to 31- 
40 years and one (10%) belonged to 41-50 years. In Group II out of 20 cases 
4(20%) belonged to 21-30 years, 9(45%) belonged to 31-40 years, 5(25%) 
belonged to 41-50 years, and 2 cases (10%) belonged to 51-60 years. In Group III 
out of 20 cases one (5%) belonged to 21-30 years, 5(25%) belonged to 31-40 
years, 2(10%) belonged to 41-50 years, 7(35%) belonged to 51-60 years, 4(20%) 
belonged to 61-70 years and 1(5%) belonged to above 70 years. In Group IV out 
of 20 cases 4(20%) belonged to 31-40 years, 6(30%) belonged to 41-50 years, 
4(20%) belonged to 51- 60 years, 3(15%) belonged to 61-70 years and 3(15%) 
belonged to above 70 years. There was a significant difference between the groups 
with respect to age (p = 0.001).(Table 1, Graph 1) 
 
Distribution of Gender among Total Study Groups: 
 In Group I, 8(80%) were males and 2(20%) were females. In Group II, 
19(95%) were males and one (5%) was female. In group III, 16 were males (80%) 
and 4(20%) were females. In Group IV, 18(90%) males and 2(10%) were females. 
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The was a significant difference between the groups with respect to gender (p = 
0.455). (Table 2, Graph 2). 
 
Distribution of Site among Total Study Groups: 
 In Group I, 7(70%) incisional biopsies were from buccal mucosa and 
3(30%) were from gingiva. In Group II, all the 20(100%) cases were from buccal 
mucosa. In Group III, 15(75%) were from buccal mucosa, 4(20%) were from 
tongue and one (5%) was from lip commissures. In Group IV, 9(45%) were from 
the buccal mucosa, 6(30%) were from gingiva, one (5%) was from hard palate and 
4(20%) were from tongue. There was a significant difference between the groups 
with respect to site (p = 0.022).  (Table 3, Graph 3) 
 
Distribution of Habits among Total Study Groups: 
The habits in the study groups are categorised as chewing & drinking 
alone, drinking & smoking alone, chewing alone, chewing, drinking & smoking 
and no habits. Within those in Group I, among total 10(100%) of the case none of 
them had any habits. In Group II,  6(30%) had the habit of chewing & drinking 
alone, 9(45%) had the habit of chewing, drinking & smoking, 5(25%) had the 
habit of chewing alone. In Group III, 13(65%) had no habits, 5(25%) had the habit 
of drinking & smoking alone, one (5%) had the habit of chewing, drinking & 
smoking and one (5%) had the habit of chewing alone. In Group IV, 16(80%) had 
no habits, 3(15%) had the habit chewing, drinking & smoking, one (5%) had the 
habit of chewing alone. There was a significant difference between the groups 
with respect to habits (p = 0.001). (Table 4, Graph 4) 
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DISTRIBUTION OF p16 STAINING AMONG STUDY GROUPS: 
 Of the total number of cases subjected to p16 staining, 16(22.9%) cases 
showed positive staining and 54(77.1%) of the cases showed negative staining. In 
Group I, out of 10 cases 5(50%) showed positivity and 5(50%) showed negative 
staining. In Group II, out of 20 cases only 7(35%) were positive for p16 
expression and 13(65%) of the cases showed negative staining. In Group III, out 
of 20 cases only one (5%) showed positivity and 19(95%) cases showed negative 
staining. In Group IV, out of 20 cases only 3(15%) showed positivity and 
17(85%) of the cases showed negative staining. There was a significant difference 
between the groups with respect to p16 positivity (p = 0.017).  (Table 5, Graph 5)  
The following parameters were used to evaluate p16 staining in all the 4 groups: 
- Staining intensity 
- Staining pattern 
- Percentage of cells stained 
- Tissue localisation of the stain 
 
Tissue Localisation of the Stain: 
 p16 staining was limited either to basal and suprabasal layers of the 
epithelium. Of the 70 cases examined, 6 showed positive staining in either basal 
or suprabasal layers or in both. In Group I, 4(40%) showed staining only in the 
basal layers of the epithelium and one (10%) showed staining in both basal and 
suprabasal layers of the epithelium. In Group II, 2(10%) showed staining only in 
the basal layers of the epithelium, 4(20%) showed staining only in the suprabasal 
layers of the epithelium, one (5%) showed staining in both basal and suprabasal 
layers of the epithelium. In Group III, one (5%) showed staining in the basal 
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layers of the epithelium. In Group IV 1(5%) showed staining in the basal layers of 
the epithelium and 2(10%) showed staining in the suprabasal layers of the 
epithelium. There was a significant difference between the groups with respect to 
staining pattern (p = 0.019). (Table 6, Graph 6) 
 
Staining Intensity: 
 Each of the positively stained cases were graded as mild, moderate and 
intense based on the intensity of p16 immunostaining. Among the 4 groups, 
9(12.9%) cases had mild intensity, 6(8.6%) cases had moderate intensity and 
1(1.4%) case showed intense staining.  
 In Group I, 4(40%) showed mild intensity and 1(10%) showed moderate 
intensity of p16 stain. In group II, 3(15%) showed mild intensity, 4(20%) showed 
moderate intensity. In Group III, 1(5%) showed mild intensity. In Group IV, one 
(5%) showed mild intensity, one (5%) showed moderate intensity and one (5%) 
showed intense staining. There was a significant difference between the groups 
with respect to staining intensity (p = 0.040).  (Table 7, Graph 7) 
 
Staining Pattern: 
 p16 staining within each cell was localised to nucleus or cytoplasm or 
membrane or in combinations between them. Out of 16 cases, 4(5.7%) cases 
revealed cytoplasmic staining. 11(15.7%) revealed staining in both nucleus and 
cytoplasm and one (1.4%) showed   staining in both cytoplasm and membrane.  
 
In Group I, only one (10%) case showed staining in cytoplasm, 3(30%) 
cases showed staining in both nucleus and cytoplasm and one (10%) case showed 
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staining in both cytoplasm and membrane. In Group II, 2(10%) cases showed 
staining in cytoplasm and 5(25%) cases showed staining in both nucleus and 
cytoplasm. In Group III, only one (5%) case showed staining in nucleus and 
cytoplasm. In Group IV, one (5%) case showed staining in cytoplasm and 2(10%) 
cases showed staining in nucleus and cytoplasm. There was no significant 
difference between the groups with respect to staining pattern (p = 0.099).  (Table 
8, Graph 8) 
 
Nuclear and Cytoplasmic Staining Grading: 
 Out of 5 cases in Group I 5 cases had negative cells per 100 cells 
examined and 2 cases had 1% to 25% of positive cells, 2 cases had 26% to 50% of 
positive cells and one case had 51% to 75% of positive cells. In group II out of 20 
cases 13 cases had negative cells per 100 cells examined, 3 cases had 1% to 25% 
of positive cells and 4 cases had 26% yo 50% of positive cells. In Group III 19 
cases had negative cells per 100 cells and one case had 1% to 26% of positive 
cells. In Group IV17 cases had negative cells per 100 cells examined, 2 cases had 
1% to 25% of positive cells and one case had 76% to 100% of positive cells. 
(Table 9) 
 
Staining Intensity Comparison between I And Group II: 
 Out of 5 cases in Group I, 4(40%) showed mild intensity and one (10%) 
showed moderate intensity.  Out of 7 cases in Group II, 3(15%) showed mild 
intensity and 4(20%) showed moderate intensity. There was no significant 
difference between the groups with respect to staining intensity (p = 0.296). 
(Table 10) 
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Staining Intensity Comparison between Group II And Group IV: 
 Out of 7 cases in Group II, 3(15%) showed mild intensity and 4(20%) 
showed moderate intensity. Out of 3 cases in Group IV one (5%) showed mild 
intensity, one (5%) showed moderate intensity and one (5%) showed intense 
staining. There was no significant difference between the groups with respect to 
staining pattern (p = 0.228). (Table 11) 
 
Staining Intensity Comparison between Group I And Group IV: 
 Out of 5 cases in Group I, 4(40%) showed mild intensity and one (10%) 
showed moderate intensity.  Out of 3 cases in Group IV, one (5%) showed mild 
intensity, one (5%) showed moderate intensity and one (5%) showed intense 
staining. There was no significant difference between the groups with respect to 
staining pattern (p = 0.080). (Table 12) 
 
Staining Pattern Comparison between Group I And Group II: 
 Out of 5 cases of Group I, one (10%) showed cytoplasmic staining, 
3(30%) cases showed both nuclear and cytoplasmic stainingand one (10%) 
showed staining in cytoplasm and membrane. Out of 7 cases of Group II, 2(10%) 
showed cytoplasmic staining and 5(25%) staining in nucleus and cytoplasm. 
There was no significant difference between the groups with respect to staining 
pattern (p = 0.510). (Table 16) 
 
Staining Pattern Comparison between Group II And Group IV: 
 Out of 7 cases of Group II, 2(10%) showed cytoplasmic staining and 
5(25%) staining in nucleus and cytoplasm. In Group IV one (5%) showed staining 
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in cytoplasm, two (10%) showed nuclear and cytoplasmic staining. There was no 
significant difference between the groups with respect to staining pattern (p = 
0.341). (Table 17) 
 
Staining Pattern Comparison between Group I And Group IV: 
 Out of 5 cases of Group I, one (10%) showed cytoplasmic staining, 
3(30%) cases showed both nuclear and cytoplasmic staining and one (10%) 
showed staining in cytoplasm and membrane. In Group IV one (5%) showed 
staining in cytoplasm, two(10%) showed nuclear and cytoplasmic staining. There 
was no significant difference between the groups with respect to staining pattern 
(p = 0.174). (Table 19) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TABLES AND GRAPHS 
TABLE 1: Age Distribution Among Total Study Groups 
 *p≤ 0.05 statistically significant 
 
 
GRAPH 1: Age Distribution Among Total Study Groups 
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S.No GROUPS 
AGE 
p 
VALUE 
21-30 31-40 41-50 51-60 61-70 ABOVE 70  
 
 
* 0.001 
1. 
GROUP I 
(n=10) 
6(60%) 3(30%) 1(10%) 0 0 0 
2. 
GROUP II 
(n=20) 
4(20%) 9(45%) 5(25%) 2(10%) 0 0 
3. 
GROUP III 
(n=20) 
1(5%) 5(25%) 2(10%) 7(35%) 4(20%) 1(5%) 
4. 
GROUP IV 
(n=20) 
0 4(20%) 6(30%) 4(20%) 3(15%) 3(15%) 
TABLE 2: Gender Distribution Among Total Study Groups 
 
S.No 
 
 GROUPS 
GENDER p 
VALUE 
MALE EMALE 
1. GROUP I (n=10) 8(80%) 2(20%)  
0.455 2. GROUP II (n=20) 19(95%) 1(5%) 
3.  GROUP III (n=20) 16(80%) 4(20%) 
4.  GROUP IV (n=20) 18(90%) 2(10%) 
*p≤ 0.05 statistically significant 
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TABLE 3: Site Distribution Among Total Study Groups 
 
 
S.No 
 
 
GROUPS 
SITE 
 
p 
BUCCAL 
MUCOSA 
GINGIVA HARD 
PALATE 
TONGUE LIP 
COMMISURES 
VALUE 
1. GROUP I 
(n=10) 
7(70%) 3(30%) 0 0 0  
*0.022 
2. GROUP II 
(n=20) 
20(100%) 0 0 0 0 
3. GROUP III 
((n=20) 
15(75%) 0 0 4(20%) 1(5%) 
4. GROUP I 
(n=20) 
9(45%) 6(30%) 1(5%) 4(20%) 0 
*p≤ 0.05 statistically significant 
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TABLE 4: Habit Distribution Among Total Study Groups 
S.No GROUPS 
HABITS 
p 
VALUE 
NO 
HABITS 
CHEWING 
& 
DRINKING 
DRINKING 
& 
SMOKING 
CHEWING, 
DRINKING 
& 
SMOKING 
CHEWING 
ALONE 
 
 
 
 
 
*0.000 
1. 
GROUP I 
(n=10) 
10(100%) 0 0 0 0 
2. 
GROUP II 
(n=20) 
0 6(30%) 0 9(45%) 5(25%) 
3. 
GROUP III  
(n=20) 
13(65%) 0 5(25%) 1(5%) 1(5%) 
4. 
GROUP IV 
(n=20) 
16(80%) 0 0 3(15%) 1(5%) 
*p≤ 0.05 statistically significant 
 
 
 
GRAPH 4: Habit Distribution Among Total Study Groups 
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TABLE 5: Distribution Of p16 Staining Among Total Study Groups 
 
S.No 
 
DIAGNOSIS 
p16 STAINING p 
VALUE POSITIVE NEGATIVE 
     1. GROUP I (n=10) 5(50%) 5(50%)  
 
*0.017 
     2. GROUP II (n=20) 7(35%) 13(65%) 
     3. GROUP III (n=20) 1(5%) 19(95%) 
     4. GROUP IV (n=20) 3(15%) 17(85%) 
*p≤ 0.05 statistically significant 
 
 
 
GRAPH 5: Distribution Of p16 Staining Among Total Study Groups 
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TABLE 6: Tissue Localisation In p16 Positive Study Groups 
S.No GROUPS 
TISSUE LOCALISATION 
P 
VALUE 
BASAL SUPRA
BASAL 
BOTH 
BASAL & 
SUPRABASAL 
NEGATIVE  
 
 
 
 
 
 
*0.019 
1 
 
GROUP I 
(n=10) 
4(40%) 0 1(10%) 5(50%) 
2 
 
GROUP II 
(n=20) 
2(10%) 4(20%) 1(5%) 13(65.0%) 
3 
 
GROUP III 
(n=20) 
1(5%) 0 0 19(95.0%) 
4 
 
GROUP IV 
(n=20) 
1(5%) 2(10%) 0 17(85.0%) 
*p≤ 0.05 statistically significant 
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TABLE 7: p16 Staining Intensity Among p16 Positive Study Groups 
 
S.No 
 
GROUPS 
p16 STAINING 
P 
VALUE 
MILD MODERATE INTENSE NEGATIVE  
 
 
 
*0.040 
1. 
GROUP I 
(n=10) 
4(40%) 1(10%) 0 5(50%) 
2. 
GROUP II 
(n=20) 
3(15%) 4(20%) 0 13(65%) 
3. 
GROUP III 
(n=20) 
1(5%) 0 0 19(95.0%) 
4. 
GROUP IV 
(n=20) 
1(5%) 1(5%) 1(5%) 17(85.0%) 
*p≤ 0.05 statistically significant 
 
 
GRAPH 7: p16 Staining Intensity Among p16 Positive Study Groups 
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 TABLE 8: Staining Pattern In p16 Positive Study Groups 
S.No GROUPS 
STAINING PATTERN 
p 
VALUE 
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0.099 
1. GROUP I 
(n=10) 
0 1(10%) 0 3(30%) 0 0 1(10%) 5(50.0%) 
2. GROUP II 
(n=20) 
0 2(10%) 0 5(25%) 0 0 0 13(65.0%) 
3. GROUP 
III (n=20) 
0 0 0 1(5%) 0 0 0 19(95.0%) 
4. GROUP IV 
(n=20) 
0 1(5%) 0 2(10%) 0 0 0 17(85.0%) 
*p≤ 0.05 statistically significant 
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TABLE 9: Nuclear And Cytoplasmic Staining Grading 
GROUPS 0 1+ 2+ 3+ 4+ 
GROUP I (n=5) 5 2 2 1 0 
GROUP II(n=7) 13 3 4 0 0 
GROUP III(n=1) 19 1 0 0 0 
GROUP IV (n=3) 17 2 0 0 1 
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TABLE 10: Comparison Of p16 Staining Percentage Positivity   
        Among Positive Study Groups 
 
S.No 
 
GROUPS 
PERCENTAGE 
POSITIVITY 
P 
VALUE 
MEAN S.D MEDIAN  
 
0.925 
1. GROUP I (n=5) 53.33 5.25 55.97 
2. GROUP II (n=7) 51.80 3.43 52.92 
3. GROUP III (n=1) 52.45 - 52.45 
4. GROUP IV (n=3) 52.85 1.84 53.11 
*p≤ 0.05 statistically significant 
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GROUP IV – ORAL SQUAMOUS CELL CARCINOMA       
 
TABLE 11: Staining Intensity Comparison Between Group I And  
        Group II 
   GROUPS STAINING INTENSITY p 
VALUE MILD MODERATE 
GROUP I 4(40%) 1(10%) 
0.296 
GROUP II 3(15%) 4(20%) 
*p≤ 0.05 statistically significant 
GROUP I – NORMAL MUCOSA   
GROUP II – OSF     
TABLE 12: Staining Intensity Comparison Between Group II  
And Group IV 
GROUPS 
STAINING INTENSITY 
p 
VALUE 
   MILD MODERATE INTENSE  
0.228 GROUP II 3(15%) 4(20%) 0 
GROUP IV 1(5%) 1(5%) 1(5%) 
*p≤ 0.05 statistically significant 
GROUP II – OSF     
GROUP IV – ORAL SQUAMOUS CELL CARCINOMA 
 
TABLE 13: Staining Intensity Comparison Between Group I And  
Group IV 
GROUPS 
STAINING INTENSITY 
      p 
VALUE 
   MILD MODERATE INTENSE  
   0.080 GROUP I 4(40%) 1(10%) 0 
GROUP IV 1(5%) 1(5%) 1(5%) 
*p≤ 0.05 statistically significant 
GROUP I – NORMAL MUCOSA   
GROUP IV – ORAL SQUAMOUS CELL CARCINOMA 
 
 TABLE 14: Staining Pattern Comparison Between Group I And Group II 
S.No GROUPS 
STAINING PATTERN 
p 
VALUE 
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0.51 
1. GROUP I 
(n=10) 
0 1(10%) 0 3(30%) 0 0 1(10%) 5(50.0%) 
2. GROUP II 
(n=20) 
0 2(10%) 0 5(25%) 0 0 0 13(65.0%) 
*p≤ 0.05 statistically significant 
GROUP II – OSF     
GROUP IV – ORAL SQUAMOUS CELL CARCINOMA 
      
 
 
 
 
TABLE 15: Staining Pattern Comparison Between Group II And Group IV 
S.No GROUPS 
STAINING PATTERN 
p 
VALUE 
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0.341 
1. GROUP II 
(n=20) 
0 2(10%) 0 5(25%) 0 0 0 13(65.0%) 
2. GROUP IV 
(n=20) 
0 1(5%) 0 2(10%) 0 0 0 17(85.0%) 
*p≤ 0.05 statistically significant 
 
GROUP II – OSF     
GROUP IV – ORAL SQUAMOUS CELL CARCINOMA 
      
 
 
 
TABLE 16: Staining Pattern Comparison Between Group I And Group IV 
 
S.No GROUPS 
STAINING PATTERN 
p 
VALUE 
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0.174 
1. GROUP I 
(n=10) 
0 1(10%) 0 3(30%) 0 0 1(10%) 5(50.0%) 
2. GROUP IV 
(n=20) 
0 1(5%) 0 2(10%) 0 0 0 17(85.0%) 
*p≤ 0.05 statistically significant 
GROUP II – OSF     
GROUP IV – ORAL SQUAMOUS CELL CARCINOMA 
      
 PHOTOGRAPHS 
 
FIGURE: 1 ANTIBODY KIT 
  
 
 
 
FIGURE: 2 ARMAMENTARIUM 
  
 
 
 
 
 
FIGURE 3 : Positive control: Squamous Cell Carcinoma – cervix (H&E - x4) 
 
 
 
 
FIGURE 4 : Positive control: Squamous Cell Carcinoma – cervix (H&E - x10) 
 
 
 
FIGURE 5 : Positive control: Squamous Cell Carcinoma – cervix (H&E - x40) 
 
 
 
 
 
FIGURE 6 : Positive control: Squamous Cell Carcinoma – cervix (p16 stain - x4) 
 
 
 
FIGURE 7 : Positive control: Squamous Cell Carcinoma – cervix (p16 stain - x10) 
 
 
 
 
FIGURE 8 : Positive control: Squamous Cell Carcinoma – cervix (p16 stain - x40) 
 
Nuclear and cytoplasmic staining 
 
 
FIGURE 9 : p16 staining in the basal and suprabasal layers of epithelium in  
normal oral mucosa (Group I - x4) 
 
Nuclear and cytoplasmic staining 
FIGURE 10 : p16 staining in the basal and suprabasal layers of epithelium in  
normal oral mucosa (Group I - x10) 
 
Nuclear and cytoplasmic staining 
FIGURE 11 : p16 staining in the basal and suprabasal layers of epithelium in  
normal oral mucosa (Group I - x40) 
 
Nuclear and cytoplasmic staining 
FIGURE 13 : p16 staining in the basal layers of epithelium in OSF (Group II - x10) 
 
Cytoplasmic staining 
 
 
FIGURE 14 : p16 staining in the basal layers of epithelium in OSF (Group II - x40) 
 
Cytoplasmic staining 
 
 
FIGURE 16 : p16 staining in the basal layers of epithelial dysplasia (Group III - x10) 
 
Cytoplasmic staining 
 
 
FIGURE 17 : p16 staining in the basal layers of epithelial dysplasia (Group III - x40) 
 
Cytoplasmic staining 
 
 
FIGURE 18 : p16 staining in OSCC (Group IV - x10) 
 
Nuclear and cytoplasmic staining 
 
 
 
FIGURE 19 : p16 staining in OSCC (Group IV - x40) 
 
Nuclear and cytoplasmic staining 
53 
 
DISCUSSION 
 
 Oral squamous cell carcinoma (OSCC), is the sixth most common cancer 
worldwide and the third most common form of cancer in the developing countries. 
The incidence of OSCC has increased due to increased risk factors such as 
tobacco and alcohol. OSCC usually arise from cells undergoing genetic and 
epigenetic alterations particularly in oncogenes or tumour suppressor genes
76
.  
 
The gene methylation is a common epigenetic event in the mammalian 
genome which involves addition of methyl group to the cytosol ring of the DNA 
base pairs resulting in CpG dinucleotide. Gene methylation also forms small 
unmethylated regions called CpG islands. There is increasing evidence suggesting 
the involvement of hypermethylation of CpG islands in different neoplasms. 
Hypermethylation denotes repeated methylation of CpG islands in the promoter 
site region of the p16 gene
10,11
.  
 
 Carcinogenesis is a process involving dysregulation of cell cycle. p16 
cyclin dependent kinase inhibitor (CKI) inhibits cyclin dependent kinases 4,6 and 
its complex with cyclin D. Thereby it also inhibits dephosphorylation and 
suppression of retinoblastoma (Rb) protein and also control other transcription 
factor responsible for transcription. All these activities together are known as 
p16INK4a/CDK4/cycD1/Rb pathway
66
.  
 
p16 immunohistochemistry has been shown to be a reliable marker for 
squamous dysplasia in uterine cervix
66,67
. In uterine cervix, p16 is overexpressed 
54 
 
due to infection of oncogenic strains of HPV. p16 overexpression is due to 
inactivation of pRb by HPV E7 oncoprotein. pRb-E7 complex releases E2F 
transcription factor which inhibits p16 gene transcription and translation resulting 
in increased expression. It has been shown that it can be also used for diagnosing 
dysplasia in cervix.  
 
In oral cavity also, similar overexpression of p16 due to inactive Rb by 
HPV leading to malignant transformation has been reported
63
.  
 
It has been reported recently that overexpression of p16 in oral potentially 
malignant and malignant lesions has also been attributed to gene inactivating 
mechanisms such as hypermethylation, homozygous deletion and point 
mutation
10,16,74
.  
 
 Given the fact that p16 has a vital role in the carcinogenesis, its association 
with HPV and its involvement in OSCC of head and neck it is important to 
identify the expression of p16 in oral potentially malignant and malignant 
lesions
39
.  
 
Given the known association of p16 and HPV in the dysplastic lesions; 
histopathologically those cases which were suggestive of HPV were included in 
the study.  
 
SAMPLE CHARACTERISTICS: 
 There was a significant difference in the age of the patients enrolled 
between the 4 groups wherein 65% of patients in OSF were in the age group of 
55 
 
21-40 years, 35% of patients with epithelial dysplasia and 50% of patients with 
OSCC belonged to age group of 31-50 years. These differences in age group in 
OSF and epithelial dysplasia and OSCC could be due to the fact that, those who 
were chewing arecanut and subsequently developed OSF belonged to the younger 
age group
10
. 
 
 There was a significant difference in gender among the groups and we 
would like to highlight that in group II, 95% were males compared to females, this 
is because of the prevalence  of chewing arecanut was more commonly observed 
in males than females.  
 
 There was a significant difference in the site distribution among the study 
groups. Though majority of the cases were from buccal mucosa 25% in group III 
and IV were from the tongue.  
 
Prevalence of habit varies significantly between the groups. The most 
interesting observation was that, of the randomly selected cases 65% in group III 
and 80% in group IV were without any habits.  
 
p16 EXPRESSION IN EPITHELIAL DYSPLASIA: 
Bradley et al stated that frequent inactivation of p16 during early 
carcinogenesis has necessitated the further investigations towards utilising p16 as 
a surrogate marker for dysplasia
32
. Immunohistochemical evaluation of oral 
premalignant and malignant lesions for p16 expression has given variable results 
56 
 
with some studies showing reduced expression
7,8 
and others showing increased 
expression
62
.  
 
In our study, only 1 case of epithelial dysplasia expressed p16 and all 
others did not. Five cases of normal mucosa expressed p16 and 5 did not. The 
repeated loss of p16 gene expression in dysplastic mucosa could be expected to 
result in reduction of p16 protein expression in dysplasia when compared to 
normal mucosa. 
 
In our study, the staining was limited to basal and suprabasal layer. This 
finding was similar to that of Bradley et al who reported that when the staining of 
p16 was present, it was confined to the basal and suprabasal cell layers in both 
normal and markedly dysplastic mucosa with no cases showing full thickness 
positivity. These findings indicate heterogenous expression of p16 within 
morphologically homogenous tissue. And thus, we agree with Bradley et al that 
p16 cannot be reliable in differentiating between normal and dysplastic mucosa
32
. 
 
It has been established that in uterine cervix, squamous dysplastic 
proliferative lesions frequently over express p16 with infection of high risk HPV 
types wherein p16 over expression has been attributed to Rb-E2F complex which 
normally inhibits transcription of p16 gene. Expression of HPV E7 results in 
excessive and dysregulated transcription and translation of p16. 
 
It is now established that overexpression of p16 may serve as a biomarker 
for HPV induced oral dysplasia and carcinoma
36,74
. 
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Mingli et al gave an alternative explanation to the reduced expression of 
p16 stating that epigenetic mechanisms such as aberrant methylation of p16, DAP-
K and MGMT genes could play a role in progression of premalignant lesions to 
cancer
34
. 
 
 Takeshima et al reported hypermethylation in 18% of mild dysplasia cases 
and 55% of severe dysplasia cases. Their study also concluded that hyper 
methylation may be involved in the pathogenesis of epithelial dysplasia
45
.  
 
p16 EXPRESSION IN OSF: 
Few studies have explained the role of p16 in the pathogenesis of OSF. In 
our study, expression of p16 was seen in 35% of cases of OSF. None of the OSF 
cases exhibited epithelial dysplasia. Takeshima et al studied 10 cases of OSF 
without epithelial dysplasia and they assessed CpG island hypermethylation by 
methylation specific PCR method.70% of their cases expressed CpG islands by 
hypermethylation. This hypermethylation may lead to the suppression of 
transcription which induces malignant transformation
45
. The detection of 
hypermethylation in OSF may predict a risk of malignant transformation.  
 
Wing YP et al explored and stated that the HPV status of tumours not 
staining strongly for p16 is difficult to interpret and may require a molecular 
technique. They further attempted to determine the staining pattern in equivocal 
p16 staining and its correlation to the percentage of positively stained tumour cells 
and analyse if it is predictive of HPV status. Their study showed strong 
association of membranous and cytoplasmic staining of isolated cells with 
58 
 
negative HPV status and concomitant faint diffuse nuclear, cytoplasmic staining 
with positive HPV status. HPV negative cases had only 30% positively stained 
tumour cells. HPV positive cases had 50%-90% positively stained tumour cells. 
They concluded that a diffuse nuclear and cytoplasmic staining pattern regardless 
of intensity is associated with HPV positivity. The HPV positive cases determined 
by staining pattern were also associated with higher percentage of tumour cells. 
When we extrapolate the results from Wing YP et al to our study of OSF, of the 7 
cases which expressed p16 five cases showed nuclear and cytoplasmic expression 
and 2 showed only cytoplasmic expression
56
. A diffuse concomitant cytoplasmic 
and nuclear staining with 50% of cells showing p16 positivity could probably be 
due to coexisting HPV infection as stated by Chen ZW et al
76
. 
 
Muirhead et al in their study which they had done to correlate the 
expression of p16 and retinoblastoma protein stated that there could be a possible 
link between morphology and cell cycle regulation protein expression in 
squamous cell carcinoma of oral cavity. They stated that correlation of p16 to a 
morphological finding was unexpected. Their study showed that of the 6 tumours 
which were positive for p16 expression (or) negative for RB protein expression 
showed a marked non keratinising appearance or poor differentiation. Thus the 
tumours that exhibited p16 had significant characteristics of cells with 
predominantly non keratinised poorly differentiated morphology
63
. In our study 
there were significant differences between the 4 groups with respect to localised 
staining in basal and suprabasal layers. Of the 7 cases of OSF, four of them 
showed suprabasal staining. Based on the findings of Muirhead et al we could 
consider these cases could represent non keratinising appearance and this could be 
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indicative of poor differentiation. Thus we postulate that p16 expression in OSF 
could be an indicator of malignant transformation
63
.  
 
We postulate that p16 could probably be involved in the malignant 
transformation of OSF to OSCC. Alternatively, we should also elicit the role of 
HPV in OSF, given the p16-HPV pathway which has been strongly proven in 
cervical cancers
48
. 
 
p16 EXPRESSION IN OSCC: 
Only15% of OSCC in our study expressed p16.WingYPet al in their study 
of HNSCC reported 48% of reduction in p16 expression. Based on this finding, 
they concluded that p16 expression is frequently reduced in HNSCC
56
. Fregonesi 
et al also correlated the expression of HPV with p16 and concluded that high risk 
HPV types are involved in p16 overexpression due to viral integration and 
malfunction of tumor suppressor protein contributing to multistep oral 
carcinogenesis
35
. 
 
Nilsson et al characterised the expression of p16, Rb phosphorylation and 
proliferation in invasive SCC of skin. The expression of p16 varied between the 
lesions. Invasive SCC showed nuclear and cytoplamic p16 expression pattern 
where some tumours had a strong cytoplasmic p16 expression. This staining was 
confined by Western Blot and band corresponding to SCC exhibiting only 
cytoplasmic p16 staining by IHC which indicated a true p16 staining in the 
cytoplasm. They could not elicit a reason as to why p16 was localised to 
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cytoplasm but proposed that it could be caused by mutation prohibiting 
translocation to the nucleus
60
. 
 
In our study of the 3 OSCC cases which expressed p16, two cases had both 
nuclear and cytoplasmic staining. Based on the results of Wing YP et al we 
interpret that one case of OSCC which had both nuclear and cytoplasmic staining 
also had more than 76% of cells expressing p16 and this finding could be probably 
associated with HPV infection. 
 
Nilsson et al contributed to explain that the exclusive cytoplasmic staining 
of p16 could be due to its mutation prohibiting the translocation to the nucleus. 
They also stated that nuclear and cytoplasmic staining is due to combination of 
high proliferation, lack of Rb-phosphorylation and high p16INK4a expression 
therefore indicating the presence of an inactive Rb-pathway
60
.  
 
Lewis et al in a study of 239 cases of oropharyngeal OSCC to assess risk 
stratification found that 78% of cases were positive for p16. Of these 74% were 
positive for HPV by ISH. They stated that overexpression of p16 occurs as a result 
of degradation of Rb by HPV E7 oncoprotein, as Rb normally suppress p16 
transcription and lack of Rb leads to marked overexpression of p16. In addition 
p16 is a tumour suppressor protein with a normal function of inhibiting cyclin 
dependent kinases. It is absent or weakly expressed in most non HPV related head 
and neck squamous cell carcinoma because the gene is mutated, deleted or 
methylated. They also stated that p16 is not the optimal biomarker for 
oropharyngeal squamous cell carcinoma (OPSCC) because it lacks the specificity 
61 
 
for HPV as p16 can be overexpressed by other mechanisms also. There are certain 
minority of OPSCC which are strongly p16 positive but are HPV negative. They 
further added that it could still be conceivable that p16 in their HPV negative 
neoplasms could have been involved in carcinogenic process of these tumours. 
They speculated that HPV might have been shed by the tumour cells. They stated 
that the tumour could develop independently from HPV and that they have innate 
p16 overexpression
68
. Based on their data they proposed that p16 positive, HPV 
negative oropharyngeal squamous cell carcinomas had better survival than p16 
negative squamous cell carcinomas. 
 
 Observational findings in our study showed that in addition to the 
positively stained normal mucosa, the diffuse nuclear and cytoplasmic staining 
pattern in OSF and OSCC were indicative of a possible HPV association of these 
lesions. The absence of p16 expression in dysplastic lesions should be further 
evaluated in considering p16 as a marker to differentiate dysplastic mucosa from 
normal mucosa.  
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SUMMARY AND CONCLUSION 
 
 A total of 70 patients were included in this study, comprising of 10 cases of 
normal oral mucosa (group I), 20 cases of OSF (group II), 20 cases of 
leukoplakia (group III) and 20 cases of oral squamous cell carcinoma (group 
IV). 
 In group I, 70% of biopsies were taken from the buccal mucosa, 30% were 
from the gingiva. 
 In group II, all the biopsies were taken from the buccal mucosa. 
 In group III 65% of biopsies were taken from the buccal mucosa, 20% were 
from tongue and 10% from gingiva and 5% from lip commissures. 
 In group IV 45% biopsies were taken from buccal mucosa, 30% were from 
gingiva, 20% were from tongue and 5% from hard palate.  
 In group II 45% of patients had chewing tobacco, drinking and smoking habits 
and 30% of patients had the habit of chewing tobacco and drinking and 25% 
of patients had the habit of chewing tobacco alone.  
 In group III 65% of patients had no oral habits, 25% of patients had the habit 
of drinking and smoking, 5% of patients had the habit of chewing tobacco, 
drinking and smoking and 5% of patients had the habit of chewing alone.  
 In group IV, 80% of patients had no oral habits, 15% of patients had the habit 
of chewing tobacco, drinking and smoking and 5% of patients had the habit of 
chewing alone. 
 In group III all the 20 cases showed features of dysplasia histologically, with 
80% mild dysplasia, 15% moderate dysplasia and 20% severe dysplasia. 
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 Out of 20 cases in group IV, 55% were well differentiated OSCC, 30% were 
moderately differentiated OSCC, 15% were poorly differentiated OSCC. 
 All the 70 samples were examined for the expression of p16 monoclonal 
antibody immunohistochemically using Poly Horse Radish Peroxidase. 
 p16 staining was evaluated by counting the percentage of cells stained per 100 
cells examined, by recording the intensity of the stain and also by examining 
the cellular location and nature of the stain. 
 35% in group II, 5% in group III, 15% in group IV showed positivity when 
compared to 50% of controls in group I. 
 Out of 70 cases 12.9% of cases showed mild intensity, 8.6% of cases showed 
moderate intensity and 1.4% of cases showed intense staining intensity. 
 Tissue localisation of the stain in the basal and suprabasal layers showed 
significant difference between the groups with four cases of OSF exhibiting 
suprabasal staining. Suprabasal staining of p16 could be indicative of loss of 
keratinisation and poor differentiation and thus could be an early marker of 
malignant transformation of OSF.   
 The pattern of p16 staining(70 cases) showed 4(5.75%) cases having 
cytoplasmic staining, 11(15.7%) cases having nuclear and cytoplasmic 
staining and one(1.4%) case had cytoplasmic and membrane staining. 
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CONCLUSION: 
In this study we addressed the association particularly between p16 and 
OSF, epithelial dysplasia and OSCC. The results of this study with respect to 
OSF data, highlights that p16 could play a role in malignant transformation of 
OSF and we hypothesize that it could be associated with HPV.  
 
 Further studies should ascertain the HPV status of the cases to be included, 
with a larger sample size to establish and understand if p16 expression could 
have a role in oral potentially malignant lesions and OSCC.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
65 
 
BIBLIOGRAPHY 
1. Uma Swaminathan, Elizabeth Joshua, Kannan Ranganathan, 
Umadevi. K.Rao. 
Expression of p53 and cyclin D1 in oral squamous cell carcinoma and 
normal mucosa: an immunohistochemical study.  
JOMFP vol 116 issue may-aug 2012. 
2. Joel Smith, Tim Rattay, Chris Mcconkey, Tim Helliwell, Hisham 
Mehanna. 
Biomarkers in dysplasia of the oral cavity: A systematic review.  
Oral Oncology 2009; 45:647-653. 
3. Ravi Mehrotra, Anurag Gupta, Mamta Singh, Rahela Ibrahim. 
Application of cytology and molecular biology in diagnosing premalignant 
or malignant oral lesions. 
Mol Cancer 2006; 5(11): 1-10 
4. Aline Correa Abrahao, Beatriz Venturi Bonelli, Fábio Daumas Nunes, 
Eliane Pedra Dias, Márcia Grillo Cabral. 
Immunohistochemical expression of p53, p16 and hTert in oral squamous 
cell carcinoma and potentially malignant disorders. 
Braz Oral Res. 2011 Jan-Feb;25(1):34-41. 
5. Jens J. Pindborg, D.D.S., Dr. Odont., Copenhage, Denmark, and 
Sntyuzmti M. Sirsat. 
Oral submucous fibrosis. 
O.S,O.M.and O.P, Volume 22 number 6 1996. 
 
 
66 
 
6. Robert L Ferris, Jennifer R Grandis. 
NF-κb Gene Signatures and p53 Mutations in Head and Neck Squamous 
Cell Carcinoma. 
Clin Cancer Res 2007;13(19); 5663-5664 
7. Vali Papadimitrakopoulou, Julie Izzo, Scott M Lippman, Jin Soo Lee, 
You Hong Fan, Gary Clayman, Jay Y Ro, Walter N Hittelman, 
Reuben Lotan, Waun K Hong and Li Mao. 
Frequent inactivation of p16ink4a in oral premalignant lesions. 
Oncogene (1997) 14, 1799-1803 
8. Andre L Reed, Joseph Califano, Paul Cairns. 
High frequency of p16(CDKN2/MTS-1/INK4A) inactivation in head and 
neck squamous cell carcinoma. 
Cancer Res 1996;56:3630-3633. 
9. DG Johnson and CL Walker 
Cyclins and cell cycle check points 
Annu.Rev.Pharmacol.Toxicol. 1999.39:295-312 
10. Marcos Malumbres and Mariano Barbacid 
To cycle or not to cycle: A critical decision in cancer 
Nature Review -  Cancer; Volume 1; December 2001 
11. Marcos Malumbres and Mariano Barbacid  
Cell cycle, cdks and cancer: a changing paradigm 
Nature Reviews – Cancer Volume 9; March 2009 
12. MH Lee and HY Yang 
Negative regulators of cyclin-dependent kinases and their roles in cancers 
CMLS, Cell. Mol. Life Sci. Vol. 58, 2001, 1907-1922 
67 
 
13. William D Foulkes 
The CDKN2A (p16) gene and Human cancer 
Molecular Medicine, Volume 3, Number 1, January 1997 5-20 
14. Charles J.Sherr 
Cancer cell cycles 
Science- Volume 274;December 1996 
15. Tsantoulis PK, Kastrinakis NG, Tourvas AD, Laskaris G,Gorgoulis VG 
Advances in the Biology of Oral cancer 
Oral Oncology (2007) 43, 523– 534  
16. Marcos Malumbres, Mariano Barbacid  
Mammalian cyclin dependent kinases 
Trends in biochemical Sciences Col.30 No.11 Nov 2005 
17. Manuel Serrano, Gregory J.Hannon, David Beach 
A New regulatory motif in cell cycle control causing specific inhibition of 
cyclin D/CDK4 
Nature Reviews - Cancer – Volume 366 – 1993 
18. Sun WTam, JerryWShay, Michele Paganoa  
Differential Expression and Cell Cycle Regulation of the Cyclin-dependent 
Kinase 4 Inhibitor p161nk4 
Cancer Research 54, 5816-5820, November 15, 1994 
19. Li Mao, Adrian Merlo, Gauri Bedi, 
A Novel  p16ink4a transcript 
Cancer Res 1995;55:2995-2997 
20. Steven Stone, Ping Jiang, Priya Dayananth 
Complex structure and regulation of the P16(MTS1) locus 
Cancer Res 1995;55:2988-2994 
68 
 
21. Christian M Beauseajour, Ana Krtolica, Francesco Galimi, Masashi 
Narita, Scott W Lowe, Paul Yaswen and Judith Campisi 
Reversal of human cellular senescence: roles of the p53 and p16 pathways 
The EMBO Journal Vol. 22 No. 16 pp. 4212±4222, 2003 
22. Naoko Ohtani, Kimi Yamakoshi, Akiko Takahashi, and Eiji Hara 
The p16INK4a-RB pathway : molecular link between cellular senescence 
and tumor suppression 
The Journal of Medical Investigation Vol. 51 2004 
23. James G Herman, Adrian Merlo, Li Mao, 
Inactivation of the CDKN2/p16/MTS1 Gene Is Frequently Associated with 
Aberrant DNA Methylation in All Common  Human Cancers 
Cancer Res 1995;55:4525-4530 
24. William D Foulkes  
The CDKN2A (pl6) Gene And Human Cancer 
Molecular Medicine, Volume 3, Number 1, January 1997 
25. Felix C. Tanner, Manfred Boehm, Levent M. Akyurek, Hong San, Zhi 
Yong Yang,  Jun Tashiro, Gary J. Nabel, Elizabeth G. Nabel, 
Differential Effects of the Cyclin-Dependent Kinase Inhibitors p27Kip1, 
p21Cip1, and p16Ink4 on Vascular Smooth Muscle Cell Proliferation 
Circulation. 2000;101:2022-2025 
26. R Mathewa, S Aroraa, R Khannaa, M Mathur, NK Shukla, R 
Ralhana 
Alterations in p53 and prb pathways and their prognostic significance in 
oesophageal cancer 
European Journal of Cancer 38 (2002) 832–841 
69 
 
27. Galina Volgareva, Larisa Zavalishina, Yulia Andreeva, Georgy 
Frank, Ella Krutikova, Darya Golovina, Alexander Bliev, Dimitry 
Spitkovsky, Valeriya Ermilova and Fjodor Kisseljov 
Protein p16 as a marker of dysplastic and neoplastic alterations in cervical 
epithelial cells 
BMC Cancer 2004, 4:58 
28. Luciano Artese, Giovanna Iezzi, Adriano Piattelli, Corrado Rubini, 
Gaia Goteri, Vittoria Pernotti, Marcello Piccirilli, Francesco Carinci 
P16 Expression in Odontogenic Cysts 
Dent Res J 2008; 5(2):61-64 
29. Brad W. Neville, Terry A.Day 
Oral cancer and precancerous lesions 
CA Cancer J Clin 2002;52:195-215 
30. Gillian L Hall, Richard J Shaw, E Anne Field 
p16 promoter methylation is a potential predictor of malignant 
transformation of epithelial dysplasia  
Cancer epidemiol biomarker prev 2008;17(8) 
31. Zhi Wang, Xiaodong Feng, Xinyu Liu, Lu Jiang, Xin Zeng, Ning Ji, 
Jing Li, Longjiang Liand Qianming Chen 
Involvement of potential pathways in malignant transformation from oral 
leukoplakia to oral squamous cell carcinoma revealed by proteomic 
analysis 
BMC genomics 2009,10:383 
 
 
70 
 
32. Kyle T Bradley, Steven D Budnick and Sanjay Logani 
Immunohistochemical detection of p16ink4a in dysplastic lesions of the 
oral cavity 
Modern Pathology (2006) 19, 1310–1316 
33. Francesca Angiero, Angiola Berenzi, Anna Benetti, Elisa Rossi, 
Rachele Del Sordo, Angelo Sidoni, Michele Stefani And Enrico Dessy 
Expression of P16, P53 and Ki-67 Proteins in the Progression of Epithelial 
Dysplasia of the Oral Cavity 
Anticancer Research 28: 2535-2540 (2008) 
34. Mingli Liu, Lei Feng, Ximing Tang, Shanchun Guo 
Gene promoter hypermethylation in leukoplakia of the oral mucosa 
Pathology and laboratory medicine international 2010;2:71-77 
35. Paula Andrea Gabrielli Fregonesi, Debora Barreto Teresa, Roberta 
Aparecida Duarte, Carlos Benatti Neto, Maria Rita Brancini de 
Oliveira, and Christiane Pienna Soares 
p16INK4a Immunohistochemical Overexpression in Premalignant and 
Malignant Oral Lesions Infected with Human Papillomavirus 
J Histochem Cytochem October 2003 vol.51 no.10 1291-1297. 
36. Martha Bouda, Vassilis G. Gorgoulis 
“High Risk” HPV Types Are Frequently Detected in Potentially Malignant 
and Malignant Oral Lesions, But Not in Normal Oral Mucosa 
Mod Pathol 2000;13(6):644–653 
37. Rooban T, Saraswathi TR, George A, Joshua E, Ranganathan K. 
Cytological study of copper in oral submucous fibrosis. 
Indian Journal of Dental Research, 2004, 15(4):129-132 
71 
 
38. WM Tilakaratne, MF Klinikowski, Takashi Saku, TJ Peters, Saman 
Warnakulasuriya 
Oral submucous fibrosis: Review on aetiology and pathogenesis 
Oral Oncology (2006) 42, 561– 568. 
39. P. Rajalalitha, S. Vali  
Molecular pathogenesis of oral submucous fibrosis – a collagen metabolic 
disorder 
J Oral Pathol Med (2005) 34: 321–8 
40. Murti PR, Bhonsle RB, Pindborg JJ, Daftary DK, Gupta PC, Mehta FS 
Malignant transformation rate in oral submucous fibrosis over a 17-year 
period 
Community Dent Oral Epidemiol. 1985 Dec;13(6):340-1.  
41. Radhakrishna Pillai, Prabha Balaram and Kannan Sankara Reddiar 
Pathogenesis of Oral Submucous Fibrosis-Relationship to Risk Factors 
Associated With Oral Cancer 
Cancer April 25, 2992, Volume 69, No. 8 
42. JH Jeng, MC Chang  
Role of areca nut in betel quid-associated chemical carcinogenesis: current 
awareness and future perspective. 
Oral Oncol. 2001 Sep;37(6):477-92 
43. N Afroz, SA Hasan, S Naseem 
Oral Submucous Fibrosis A Distressing Disease with Malignant Potential 
Indian Journal of Community Medicine Vol. 31, No. 4, October-
December, 2006 
 
72 
 
44. Siddharth Pundir, Susmita Saxena, Pooja Aggrawal 
Oral submucous fibrosis a disease with malignant potential - Report of two 
Casess 
J Clin Exp Dent. 2010;2(4):e215-8 
45. Maiko Takeshima, Masato Saitoh 
High frequency of hypermethylation of p14, p15 and p16 in oral pre-
cancerous lesions associated with betel-quid chewing in Sri Lanka 
JOPM volume 37, Issue 8, pages 475–479, September 2008 
46. L Fung  
Expression and Significance of Fragile Histidine Triad, P16 in Oral 
Submucous Fibrosis and OSF Concomitant with OSCC 
Taiwan oncology educational book 2010 
47. H K Williams 
Molecular pathogenesis of oral squamous carcinoma 
J clinpathol: molpathol 2000;53:165–172 
48. V Patel, C Ieethanakul and JS Gutkind 
New Approaches To the Understanding of the Molecular Basis of Oral 
Cancer 
CROBM 2001 12: 55 
49. B Perez Ordonez, M Beauchemin, RCK Jordan 
Molecular biology of squamous cell carcinoma of the head and neck 
J Clin Pathol 2006;59:445–453 
 
 
73 
 
50. Joao Massano, Frederico S Regateiro, Gustavo Januario and Artur 
Ferreira 
Oral squamous cell carcinoma: Review of prognostic and predictive 
factors 
OOOE 2006;102:67-76 
51. Crispian Scully, Jose V Bagan, Colin Hopper, Joel B. Epstein, 
Oral cancer: Current and future diagnostic techniques 
Am J Dent 2008;21:199-209 
52. J. Campo-Trapero1, J. Cano Sanchez, B Palacios Sanchez, Jj. Sánchez 
Gutierrez, MA Gonzalez Moles and A Bascones-Martínez 
Update on Molecular Pathology in Oral Cancer and Precancer 
Anticancer Research 28: 1197-1206 2008 
53. Philip Lazarus, Sabina N Sheikh 
P53, but not p16 mutations in oral squamous cell carcinomas are 
associated with specific CYP1A1 and GSTM1 polymorphic genotypes and 
patient tobacco use 
Carcinogenesis vol.19 no.3 pp.509–514, 1998 
54. M Sartor, H Steingrimsdottir, F Elamin, J Gäken, S 
Warnakulasuriya, M Partridge, N Thakker, NW Johnson and M 
Tavassoli 
Role of p16/MTS1, cyclin D1 and RB in primary oral cancer and oral 
cancer cell lines 
British Journal of Cancer (1999) 80(1/2), 79–86 
74 
 
55. Ming J Poi, Thomas Yen, Junan Li, Huijuan Song, Jas C Lang, David 
E Schuller, Dennis K Pearl, Bruce C Casto, Ming Daw Tsai and 
Christopher M Weghorst 
Somatic INK4a-ARF Locus Mutations: A Significant Mechanism of Gene 
Inactivation in Squamous Cell Carcinomas of the Head and Neck 
Molecular Carcinogenesis 30:26-36 2001 
56. P Wing Yuen, M Man, K Yin Lam, Y Lam Kwong 
Clinicopathological significance of p16 gene expression in the surgical 
treatment of head and neck squamous cell carcinomas 
J clinpathol 2002;55:58–60 
57. Stacy A Geisler, Andrew F Olshan, Mark C Weissler 
P16 and p53 Protein Expression as Prognostic Indicators of survival and 
disease recurrence from head and neck cancer 
Clin Cancer Res 2002;8:3445-3453 
58. Muthusamy Viswanathan, Nobuo Tsuchida and Govindaswamy 
Shanmugam 
Promoter hypermethylation profile of tumour associated genes p16, p15, 
hmlh1, MGMT and E-Cadherin in Oral squamous cell carcinoma 
Int. J. Cancer: 105, 41–46 2003 
59. Lingbao Ai, Krystal K Stephenson, Wenhua Ling, Chunlai Zuo, 
Perkins Mukunyadzi, James Y Suen, Ehab Hanna, Chun Yang Fan 
The p16 (CDKN2a/INK4a) Tumor-Suppressor Gene in Head and Neck 
Squamous Cell Carcinoma: A Promoter Methylation and Protein 
Expression Study in 100 Cases  
Mod Pathol 2003;16(9):944–950 
75 
 
60. Kristina Nilsson, Sofie Svensson and Goran Landberg  
Retinoblastoma protein function and p16INK4a expression in actinic 
keratosis, squamous cell carcinoma in situ and invasive squamous cell 
carcinoma of the skin and links between p16INK4a expression and 
infiltrative behaviour  
Modern Pathology (2004) 17, 1464–1474 
61. Paul M Weinberger, Z Yu, BG Haffty 
Prognostic Significance of p16 Protein Levels in oropharyngeal squamous 
cell cancer  
Clin Cancer Res 2004;10:5684-5691 
62. Jeong Keun Lee, Myung-Jin Kim, Sam Pyo Hong and Seong Doo 
Hong 
Inactivation patterns of p16/INK4A in oral squamous cell carcinomas  
Experimental and Molecular Medicine, Vol. 36, No. 2, 165-171, April 
2004 
63. DM Muirhead, HT Hoffman, RA Robinson 
Correlation of clinicopathological features with immunohistochemical 
expression of cell cycle regulatory proteins p16 and retinoblastoma: 
distinct association with keratinisation and differentiation in oral cavity 
squamous cell carcinoma  
Clinpathol 2006;59:711–715 
64. Eleftherios Vairaktaris, Christos Yapijakis, Amanda Psyrri, Sofia 
Spyridonidou, Athanasios Yannopoulos, Andreas Lazaris, Stavros 
Vassiliou, Eleftherios Ferekidis, Antonis Vylliotis, Emeka Nkenke And 
Efstratios Patsouris 
76 
 
Loss of Tumour Suppressor p16 Expression in Initial Stages of Oral 
Oncogenesis 
Anticancer Research 27: 979-984 (2007)  
65. LP Dragomir, Cristiana Simionescu, CL Margaritescu, A Stepan, 
Iuliana Manuela Dragomir, Mr Popescu 
P53, p16 and Ki67 immunoexpression in oral squamous carcinomas 
Rom J Morphol Embryol 2012, 53(1):89–93 
66. Harriet C Hafkamp, Ernst Jm Speel, Annick Haesevoets, Fredrik J 
Bot, Winand N.M. Dinjens, Frans C.S. Ramaekers, Anton H.N. 
Hopman, and Johannes J. Manni 
A subset of head and neck squamous cell carcinomas exhibits integration 
of hpv 16/18 dna and overexpression of p16ink4a and p53 in the absence 
of mutations in p53 exons 5–8  
Int. J. Cancer: 107, 394–400 2003 
67. Aimee R Kreimer, Gary M Clifford, Peter Boyle 
Human Papillomavirus Types in Head and Neck Squamous cell 
carcinomas worldwide: A Systematic Review 
Cancer Epidemiol Biomarkers Prev 2005;14:467-475 
68. James S Lewis, Wade L Thorstad, Rebecca D Chernock, Bruce H 
Haughes,  James H Yip, Qin Zhang, and Samir K El Mofty 
p16 Positive Oropharyngeal Squamous Cell Carcinoma: An Entity With a 
Favorable Prognosis Regardless of Tumor HPV Status  
Am J surgpathol Volume 34, Number 8, August 2010 
 
 
77 
 
69. Andrew W. Joseph, BS, and Sara I. Pai 
Human Papillomavirus and the Shifting Trends in Head and Neck Cancer 
American Society of Clinical Oncology - 2011 
70. MA O’Rorke, MV Ellison, LJ Murray, M Moran, J James, LA 
Anderson  
Human papillomavirus related head and neck cancer survival: A 
systematic review and meta-analysis 
Oral oncology 2012 
71. Jaana Rautava, Jonna Kuuskoski, Kari Syrjänen, Reidar Grenman, 
Stina Syrjanen 
HPV genotypes and their prognostic significance in head and neck 
squamous cell carcinomas 
Journal of Clinical Virology 53 (2012) 116– 120 
72. X Dufour, A Beby Defaux, G Agius, J Lacau St Guily 
HPV and head and neck cancer 
European Annals of Otorhinolaryngology, Head and Neck diseases (2012) 
129, e26—e31 
73. Tatyana Isayeva, Yufeng Li, Daniel Maswahu, Margaret Brandwein 
Gensler 
Human papilloma virus in Non oropharyngeal head and neck cancers: a 
systematic literature review 
Head and neck pathol (2012) 6:s104-s120 
 
 
78 
 
74. Frank Konig, Gisbert Krekeler, Johannes F Honig, Carlos Cordon 
Cardo, Gosta Fischer and Monika Korabiowska 
Relation between Human Papillomavirus Positivity and p16 Expression in 
Head and Neck Carcinomas – A Tissue Microarray Study 
Anticancer Research 27: 283-288 (2007) 
75. Christina S Kong, Balasubramanian Narasimhan, Hongbin Cao, 
Shirley Kwok, Julianna P Erickson, Albert Koomg, Nader Pourmand, 
Quynh Thu le  
The Relationship Between Human Papillomavirus Status and Other 
Molecular Prognostic Markers in Head and Neck Squamous Cell 
Carcinoma 
Int J radiatoncolbiol Phys. 2009 June 1; 74(2): 553–561) 
76. Zhongchuan Will Chen, Ilan Weinre, Suzanne Kamel Reid, Bayardo 
Perez Ordonez 
Equivocal p16 immunostaining in squamous cell carcinoma of the head 
and neck: staining patterns are suggestive of HPV status 
Head and neck pathol (2012) 
ANNEXURE - I 
 
From, 
Institutional Review Board, 
Ragas Dental College and Hospital, 
Uthandi, 
Chennai 
 
 The dissertation topic titled “STUDY OF EXPRESSION OF p16 IN ORAL 
SQUAMOUS CELL CARCINOMA, POTENTIALLY MALIGNANT DISORDERS 
AND NORMAL MUCOSA” submitted by R.Sudharsan has been approved by the 
Institutional Review Board of Ragas Dental College and Hospital on 26
th
 September 
2011. 
 
Dr.K.Ranganathan     Dr.S.Ramachandran 
Secretary,              Chairman, 
Ragas, IRB       Ragas, IRB 
 
 
 
 
 
 
 
 
ANNNEXURE - II 
 
p16 PATHWAY: 
 
 
 
 
 
 
ANNNEXURE - III 
ABBREVIATIONS 
1. OSCC  – Oral Squamous Cell Carcinoma 
2. OSF   –  Oral Submucous Fibrosis 
3. HNSCC –  Head and Neck Squamous cell carcinoma 
4. OPSCC  –  OroPharyngeal Squamous Cell Carcinoma 
5. WHO   –  World Health Organisation 
6. p53(or)TP53 –  Protein 53 (or) Tumour Protein 53 
7. pRb   –  Phosphorylated Retinoblastoma gene 
8. p16   –  Tumour suppressor gene p16 
9. p14   –  Tumour suppressor gene p14 
10. p15  –  Tumour suppressor gene p15 
11. bcl2   –  B cell lymphoma 2 gene 
12. Bax2   –  B cell lymphoma associated X protein 
13. CDK   –  Cyclin Dependent kinases 
14. CKI   –  Cyclin Dependent Kinase Inhibitors 
15. Rb   –  Retinoblastoma gene 
16. 9p21   –  p16 gene locus 
17. CpG   –  C - phosphate – G – Cytosine and Guanine   
   nucleotide separated by phosphate 
18. HPV   –  Human Papilloma Virus 
19. E6   –  E6 Viral Oncoprotein 
20. E7   –  E7 Viral Oncoprotein 
21. IHC   – Immunohistochemistry 
22. H&E   –  Hematoxylin and Eosin 
23. LM   –  Light Microscope 
24. APES   –  Amino Propyl tri Ethoxy Silane 
25. HRP   –  Horse Radish Peroxidase 
26. DAB   –  Di Amino Benzidine 
27. DPX   –  Di Butyl Phthalate in Xylene 
28. HCL   –  HydroChloricAcid 
29. PBS   –  Phosphate Buffer Saline 
30. INK   –  Inhibitor Kinases 
31. Cip   –  Cyclin dependent kinase Inhibitor Protein 
32. Kip   –  Kinase Inhibitory Protein 
33. DNA   –  Deoxyribo Nucleic Acid 
34. ARF   –  Alternate Reading Frame 
35. E2F   –  Transcription Factor E2F Family 
36. HeLA   –  Henrietta Lacks cell line 
37. mRNA  –  Messenger Ribo Nucleic Acid 
38. cDNA   –  Complementary DNA 
39. p21   –  Kinase Inhibitory Protein p21 
40. p27   –  Kinase Inhibitory Protein p27 
41. PVL   –  Proliferative Verrucuous Leukoplakia 
42. PCR   –  Polymerase Chain Reaction 
43. PA28   –  Proteasome Activator 28 
44. Ki 67   –  Kiel 67 protein 
45. TNF   –  Tumour Necrosis Factor 
46. IL   –  InterLeukin 
47. TGF   –  Transforming Growth Factor 
48. PAI   –  Plasminogen Activator Inhibitor gene 
49. TIMP   –  Tissue Inhibitor of Matrix Metalloproteinase gene 
50. INF   –  Interferon 
51. FHIT  –  Fragile Histidine Triad 
52. RB   –  Retinoblastoma protein 
53. EGFR  –  Epidermal Growth Factor 
54. RAS   –  Rouse Avian Sarcoma 
55. EBV   –  Epstein Barr Virus 
56. C(CAP)  –  Head and Neck squamous cell carcinoma   
   specific chromosomal alterations 
57. HN-CGAP  –  Head and Neck cancer Genome Anatomy Project 
58. LCM   –  Laser Capture Microdissection 
59. RASSF1A  –  RAS associated domain containing protein 
60. PRAD1  –  Parathyroid Adenomatosis 1 gene 
61. CYP1A1  –  Cytochrome P450 family 1, Subfamily A,  
  Polypeptide 1 gene 
62. GSTM1  –  Glutathione S Transferase Mu1 gene 
63. MGMT  –  Methyl Guanine methyl Transferase 
64. LMLH1  – L Mut L Homolog1 gene 
65. FISH   –  Flourescent Insitu Hybridisation 
66. SSCP   –  Single Stranded Conformational Polymorphism 
67. MTS1   –  Multiple Tumour Suppressor 1 gene 
68. MDM2  –  Murine Double Minute Protein 
69. CCNE1  –  Conserved Cyclin E1 
70. CCND1 – Conserved Cyclin D1 
71. DAP-K  – Death Associated Protein Kinase 
72. LOH  –      Loss Of Heterozygosity 
